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Abstract
Structure-based drug design is a creative process that displays several features that 
make it closer to human reasoning than to machine automation. However, very often 
the user intervention is limited to the preparation of the input and analysis of the 
output of a computer simulation. In some cases, allowing human intervention directly 
in the process could improve the quality of the results by applying the researcher 
intuition directly into the simulation.
Haptic technology has proven to be a useful method to interact in realtime with a 
virtual environment, enriching the user’s experience and allowing for a more natural 
and direct interaction with three-dimensional systems.
Reported in this thesis is the design and implementation of a user-driven com­
puter program for structure-based drug design based on haptic technology and char­
acterised by a trimodal feedback system and its application alongside more traditional 
approaches to drug design projects in the anticancer and antiviral area.
The software proved to be very useful in several projects, validating the appli­
cability of haptic technology to drug design. The results were in good agreement 
with those obtained by traditional techniques. Moreover the approach resulted in the 
identification of novel HCV inhibitors and a putative inhibitor of the dimerisation of 
EGFR which resulted active in vitro tests.
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Chapter 1 
M olecular m odelling and drug 
design
Molecular modelling is the science (or art) of representing molecular structures nu­
merically and simulating their behavior with the equations of quantum and classical 
physics. Computational chemistry programs allow scientists to generate and present 
molecular data including geometries (bond lengths, bond angles, torsion angles), en­
ergies (heat of formation, activation energy, etc.), electronic properties (moments, 
charges, ionisation potential, electron affinity), spectroscopic properties (vibrational 
modes, chemical shifts) and bulk properties (volumes, surface areas, diffusion, viscos­
ity, etc.)[l, 2]. It is a rather new branch of theoretical chemistry and is evolving very 
fast, following the evolution of computing hardware that provides the computational 
power to carry out more and more complex calculations. The impact of molecular 
modelling on the process of drug discovery is already significant, and destined to be­
come even more important[3, 4]. In the age of human genome being deciphered and 
3-dimensional structures of proteins being made available in an increasing number, 
drugs may now be designed in advance guessing possible 3-dimensional shape of the 
targets. In drug design, potential compounds may be conceptualised for the per­
formance of required functions based on essential characteristics (pharmacophores), 
including idealised structural and physical properties. Molecular models of com­
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pounds can be built, and virtual tests may be run to assess their suitability before 
an expensive synthesis attempt is made. Virtual experiments are cheaper, faster, and 
safer than real experiments, and the data can help scientists to eliminate compounds 
that would not perform the required function. These are now essential tools for data 
management and cost-effective development processes in pharmaceutical Research 
and Developement[5].
Computer aided drug design approaches are traditionally divided into two major 
categories[6]: ligand based and structure based. Ligand based approaches rely on 
chemometric functions to compute various descriptors from the 2D or 3D structure of 
a set of molecules and use statistical methods to build correlation models to predict 
biological properties (such as activity) of compounds. Structure based approaches 
are based on the key-lock metaphor for ligand-target interaction.
This project focuses on the latter approach.
1.1 M olecular mechanics
The term molecular mechanics refers to the application of Newtonian mechanics to 
the modelling of molecular systems. In order to lower its complexity, the physical- 
mathematical description of molecules in a molecular mechanics simulation adopts 
several simplifications. Some of the most important are:
•  molecules are treated as balls-and-springs systems
•  bonds are unbreakable
•  electrons are not considered as separate entities
•  atoms are treated as solid spheres with fixed radius (typically the Van der Waais 
radius) and charge
•  atoms differ among themselves for atom-type (depending on atomic number, 
hybridisation and chemical properties)
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A molecule is therefore reduced to a set of atom types and a bonding list (Figure
1 . 1.
§<TRIPOS>HOLEaJLE
NONAME
21  21  8  0  8
SMALL
USER_CHAR6ES
§<TRIPOS>ATOH
1 C 1.3750 8.7612 8.4866 C.ar 1 <1> 8.8862
2 C 0.4240 1.4364 -8.2349 C.ar 1 <1> 8.0825
3 0 8.5773 2.8137 -8.4648 0.3 1 <1> -8.2325
4 C -8.7685 0.8436 -0.6684 C.ar 1 <1> -6.1588
5 H -1.5144 1.4326 -1.1950 H 1 <1> 8.1588
6 C -8.9999 -0.5858 -0.4119 C.ar 1 <1> -8.1568
7 H -1.9214 -0.9742 -0.7498 H 1 < 1 > 8.1588
8 C -0.0529 -1.2543 0.2876 C.ar 1 A
rHV -8.1588
9 H -8.2360 -2.3072 0.4893 H 1 < i > 8.1588
10 C 1.1277 -0.6545 8.7388 C.ar 1 < i > -8.1588
11 H 1.8476 -1.2605 1.2844 H 1 < i > 8.1588
12 C 2.6135 1.3288 8.9459 C.2 1 < i > 8.6338
13 0 3.1238 2.3398 0.4986 0.2 1 < i > -8.5780
14 0 3.1746 8.6618 1.9738 0.3 1 < i > -8.6588
15 H 3.9777 1.1747 2.2826 H 1 < i > 8.5888
16 C 1.8925 3.3169 -1.6580 C.2 1 < i > 8.6598
17 C 1.6199 2.3073 -2.6386 C.3 1 < i > 8.0618
18 H 8.8895 1.6843 -3 .8238 H 1 < i > 8.8088
19 H 2.4899 1.7822 -2.1892 H 1 < i > 8.0888
20 H 2.8617 2.8405 -3.4869 H 1 < i > 8.0008
21 0 1.8958 4.5227 -1.8986 0.2 1 < i > -8.5788
©<TRIP0S>60fC
1 1 2 ar
2 1 18 ar
3 1 12 1
4 2 3 1
5 2 4 ar
6 3 16 1
7 4 5 1
8 4 6 ar
9 6 7 1
18 6 8 ar
11 8 9 1
12 8 18 ar
13 10 11 1
14 12 13 2
15 12 14 1
16 14 15 1
17 16 17 1
18 16 21 2
19 17 18 1
20 17 19 1
21 17 20 1
Figure 1.1: Examples of parameterisation for aspirin in TRIPOS mol2 format
Although most molecular mechanics application consider each atom as a separate 
entity, variations on this theme are possible; for example, many simulations have his­
torically used a ” united-atom” representation in which methyl and methylene groups 
were represented as a single particle, and large protein systems are commonly simu­
lated using a ’’bead” model that assigns two to four particles per amino acid.
Sets of mathematical equations (forcefields) have been developed to compute var­
ious properties from this description of a molecular system. Inside the wide envi­
ronment of molecular mechanics several specific applications can be performed. The
3
following sections describe some of the most important ones in computer aided drug 
design.
1.1.1 Forcefields and scoring functions
In a molecular mechanics environment all electrons are neglected and molecular prop­
erties cannot be calculated using quantum mechanics approaches. Sets of mathemat­
ical equations (forcefields) have been developed to compute various properties from 
atomic coordinates and atom types. The derivation of a forcefield can be empirical, 
trying to fit the equations to experimental or calculated data, or ab initio, deriving 
equations from classical physics, but very often results from the combined application 
of the two approaches. Many of the forcefields currently in use can be interpreted 
in terms of a fairly simple four-component picture of the inter- and intra-molecular 
forces within the system. Energetic penalties are associated with the deviation of 
bonds and angles away from their “reference” or “equilibrium” values, there is a 
function that describes how the energy changes as bonds are rotated, and finally the 
forcefield contains terms that describe the interaction between non-bonded parts of 
the system, usually in terms of electrostatic and van der Waals interactions. More 
sophisticated forcefields may have additional terms, but they invariably contain these 
four components[1]. Examples of forcefield functions are reported in Figure 1.2.
Some existing forcefields usually do not account for electronic polarization of the 
environment, an effect that can significantly reduce electrostatic interactions of partial 
atomic charges. This problem was addressed by developing polarizable force fields 
[7] or using a macroscopic dielectric constant. However, application of a single value 
of dielectric constant is questionable in highly heterogeneous environments such as 
proteins or biological membranes [8].
Like forcefields, scoring functions are mathematical functions that relate atomic 
coordinates to energy values[9]. They are usually developed for applications such as 
molecular docking and are parameterised to reproduce the interactions of intermolec- 
ular complexes. Scoring functions are usually much simpler than forcefield functions,
4
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Figure 1.2: Examples of forcefield functions: A: MMFF94 Bond stretching energy. 
B: MMFF94 Van Der Waals interactions
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as they axe the speed determining point in, for instance, a docking algorithm. They 
usually focus on nonbonded interactions, and many of them consider bonded ener­
gies constant. Some scoring functions include empirical terms such as hydrogen bond 
energies or an estimate of the entropic loss of ligands upon binding or solvation ef­
fect. There are three major kinds of scoring functions, according to the way they are 
derived[l]:
•  Forcefield based: these functions are based on a forcefield. The main draw­
back is that forcefields are not designed to account for entropic or solvation 
effects and therefore this effects cannot be accounted for.
•  Empirical: they are designed to reproduce experimental affinity data. The 
parameters of the various energy contributions are obtained from a regression 
analysis using a training set of crystal structures of complexes and the relative 
experimental affinity data. They usually perform well and they are the most 
widely used, but they also show a strong dependence from the training set which 
might limit their applicability in some cases.
•  Knowledge-based: they are trained to reproduce experimental structural data 
instead of affinites. They are based on the assumption that atom configurations 
that are often seen in crystallographic structures are energetically favoured.
1.1.2 Energy minimisation
Molecular mechanics forcefields axe usually paxameterised directly to reproduce po­
tential energies. Using both ab-initio quantum mechanics-derived and empirical func­
tions and parameters, forcefields compute both bonded and non-bonded interaction 
energies, thus providing the total potential energy of a molecular system as a math­
ematical function of its inner variables (usually atom coordinates). The analytical 
mathematical study of the energy function (usually known to computational chemists 
as energy surface or energy landscape) provides important insight on the properties 
of the conformational states of a particular molecule or a system of molecules. A
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minim um  point in the energy function (local minimum) is associated with a stable 
state of the system. Energy minimisation finds its application in several molecular 
mechanics and dynamics experiments, such as in generating good quality conforma­
tions of a given molecule or in refining molecular docking results or homology models. 
Various standard mathematical optimisation methods can be applied to find a local 
m inim um  of the energy landscape. The general idea common to most of this min­
imisation algorithms is walking downhill on the energy surface from a starting point 
until a minimum point is reached. Obviously this method can just find one minimum 
point, the one nearest to the starting point. Sometimes, however, it is important to 
find the global minimum (the minimum point with the lowest value), for instance to 
predict the most stable conformation of a molecule under given conditions. When 
this cannot be spotted with a systematic approach (as is usually the case in molec­
ular modelling) a stochastic process is used to generate starting points for several 
minimisation runs.
Mathematically, a minimum point is one where the first derivative of the function 
with respect to each of the variables is zero and the second derivatives are all positive 
(equation 1.1).
i H 3 > «  <■»
The first partial derivative can be used to decide which way the function is go­
ing downhill for a particular variable. This, however, assumes that the function is 
derivable, which sometimes is not the case. Depending on the characteristics of the 
function, derivative methods (such as the steepest descent or the conjugate gradients 
method) or non-derivative ones (such as the simplex method) are used.
1.1.3 Docking simulation
In molecular docking simulations modelling techniques are used to predict how any 
macromolecule (typically a protein) interacts with other molecules (may be other 
proteins, nucleic acids or small drug-like molecules) [10, 11]. Small molecule-protein 
docking (usually known as protein-ligand docking) is the most frequently used as the
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smaller dimensions of the system allow for a higher accuracy of the mathematical 
description and a higher reliability of the model. Moreover it has dramatically im­
portant applications in medicinal chemistry, where it is used as the base of structure 
based drug design approaches[12]. Protein-protein docking is still at its beginning, 
as its high requirements in terms of computational power has long made it too slow 
or too inaccurate [13]. However it is developing fast and has already scored some 
impressive results.
In a docking simulation a search algorithm is used to find the global minimum of a 
scoring function. The computational description of this search (the so-called docking 
problem) is usually unsuitable to be treated with deterministic algorithms because its 
complexity grows exponentially with the number of variables and is beyond the com­
putational power of common hardware. The approaches used to solve this problem 
can be broadly classified as fragment-based methods, stochastic optimisation meth­
ods, or as multiconformer docking approaches [14].
•  Fragment based approaches consist in splitting the ligand into different rigid 
fragments and perform an incremental construction of the solution. The dock­
ing of single fragments is much easier of the one of a full molecule, as they can 
be treated as rigid bodies. An approach of this kind is employed by FlexX [15].
•  Stochastic optimisation methods imply stochastic (random) steps in the search 
to speed up the process. They cannot guarantee to find the best solution, but 
are used to find a good solution in a reasonable time. Examples of this class of 
search algorithms are the genetic algorithm used in GOLD [16] and autodock 
[17], Monte Carlo minimisation in GLIDE [18] and simulated annealing, evolu­
tionary programming, and tabu search in PROJLEADS [19].
•  Multiconformer docking is performed by pre-generating a library of low-energy 
conformations for the input molecule and docking them as rigid bodies. This is
8
the approach exploited by FRED (OpenEye).
1.1.4 Virtual screening
Virtual screening experiments are based on the application of molecular docking tech­
niques to large numbers of molecules on the same target. A common computer can 
dock a medium sized molecule with reasonable accuracy in few minutes and more 
powerful computers can further reduce this time. It has become common practice for 
pharmaceutical industries and universities to screen hundreds of thousands or even 
millions of drug-like candidates in this way to find a drug lead for a particular target. 
Each molecule-target interaction is scored and the best-scoring candidates are chosen 
for further investigation in silico or for synthesis and in vitro testing. Compared 
to traditional in-vitro high-throughput screenings, virtual screenings are orders of 
magnitude faster and less expensive[20, 21, 22, 23, 24].
A virtual screening process can be divided in three phases:
1. Docking phase: the binding pose for each molecule of the database is generated
with molecular docking.
2. Scoring phase: every molecule in the database is scored with one or more scoring 
functions and the molecules are sorted according to their predicted affinity.
3. Visual inspection: the best-ranking molecules are inspected by the user and the 
most promising ones are selected.
1.1.5 De novo drug design
De novo drug design approaches use structural information on a specific target to
build ligands which interact with the active site by means of hydrogen bonds, electro­
static and/or hydrophobic interactions. Information on the binding mode of known 
ligands, from protein-ligand complex structures, may also be used as a guide in the
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process. There axe three basic classes of computational approaches to de novo drug 
design:
•  Fragment placement determines favourable binding positions for single rigid 
fragments, which aim to capture the basic molecular interactions in the active 
site. GRID is an example of an application of this approach: its algorithm 
generates a regular grid inside the active side and then places functional group 
probes (such as hydroxyl or methyl groups) at the vertices, scoring the interac­
tion potential at each vertex and locating the best placements for each fragment.
•  Connection methods attem pt to place small molecules in the active site aiming 
to match site points (derived by rules or using the fragment placement method) 
where they would have favourable interactions. Alternatively, fragment connec­
tion methods search for scaffolds which are suitable to connect isolated frag­
ments which have favourable interactions with regions of the active site.
•  Sequential growth consists in the construction of a ligand, step by step, within 
an active site. This methodology is useful to generate new potential leads or 
optimising a known ligand by modifications introduced in its structure.
1.2 Molecular dynamics
While Molecular Mechanics is concerned with atomic interactions, three dimensional 
geometries and energies in a given moment, Molecular Dynamics (MD) aims to predict 
the evolution of a molecular system over time [25].
In MD simulations atoms and molecules are allowed to interact for a period of time 
under known laws of physics, generating a trajectory for the motion of the atoms. 
By solving Newton’s equations of classical mechanics a MD simulation is capable of 
generating successive configurations of a system of molecules and propagating the
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positions and velocities forward in time. It mimics the way molecules explore their 
conformational space in reality, being particularly suited for the conformational study 
of proteins or other large molecules [1].
The collection of forces that act on each atom i of the system in study cause 
the latter to change in a way which follows Newton’s second law of motion (Equation 
1.2).
Fi =  rriiai (1.2)
Equation 1.2 can be rearraged, given that the acceleration is the second derivative 
of the displacement s* with respect to time U yielding Equation 1.3
=  3.  ( 1 3 )
8t2 m, { '
Integration of equation 1.3 gives the displacement of each particle as a function 
of time, Ui being the initial velocity and a* the acceleration caused by Fij given by 
equation 1.4.
Si =  u{t +  +  c (1.4)
This is the key equation for MD simulations, allowing the calculations of the 
position of each atom in the system as a function of time.
Although molecular dynamics can be carried out in vacuo, unlike most molecular 
mechanics calculation it usually uses explicit solvent approaches. A box filled with 
water molecules is generated around the molecule to study, and periodic boundary 
conditions are applied (i.e. the box is surrounded by identical copies of itself, so 
whatever leaves it from one side enters back from the opposite). A typical MD 
system is shown in picture 1.3. Because molecular systems generally consist of a 
vast number of particles, it is impossible to compute the properties of such complex 
systems analytically; MD simulation circumvents this problem by using numerical 
methods.
An MD simulation usually involves 3 steps:
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• Energy m inim isation: the system is brought to a minimum of the energy 
landscape.
• Solvent equilibration: the system is allowed to evolve for a certain time with 
restrains on atomic positions. This allows the solvent to lose memory of its 
initial state.
• M olecular Dynamics: the proper molecular dynamics step.
The span of time that is simulated depends on various factor, the most importants 
being the computational power used and the time the simulation is allowed to run. 
Hower normal dynamics rarely covers more than a few tens of nanoseconds.
Figure 1.3: Example of a Molecular Dynamics system: Protein Kinase A in water
12
Chapter 2 
H aptic technology in drug design
Drug design is an extremely creative process and displays several features that make 
it closer to human reasoning than to machine automation. The traditional way to 
tackle it, however, is often a black-box approach, with the user analysing structures 
proposed by a computer algorithm without any chance of intervention on the process 
of their generation other than the setting of parameters at the beginning. This often 
leads to a number of “false positives”, with the computer wasting calculation time and 
display space on structures that are not chemically accessible, or that could be easily 
discarded by an average chemist for other reasons. Being able to avoid these wastes 
not only would save time, but would also allow a more complete exploration of the 
chemical or conformational space during a simulation, enriching it with high-quality 
results.
Current advances in hardware technology make it possible to think of approaching 
the problem from a different angle, putting the reins of drug design back into human 
hands. Ergonomics is the science of designing a process or a tool to fit the user. It is 
becoming a keyword in many aspects of life, from production tools to the entertain­
ment industry. This project is aimed to the construction of an ergonomic Molecular 
Mechanics environment for interactive, user-driven de novo drug design and ligand 
optimisation, characterised by a trimodal feedback system. The goal is to create an 
environment where the user plays an active role in the simulation, and is able to steer
13
it in real time to bring his/her own contribution to the generation of the final result.
2.1 Haptic technology
Haptic, from the Greek a(prj (Haphe), means “pertaining to the sense of touch”. A 
haptic stimulus is for the sense of touch what a visual stimulus is for the sense of sight. 
Haptic technology refers to technology which interfaces the user via the sense of touch 
by applying forces, vibrations and/or motions to him/her. This mechanical stimula­
tion is used to create haptic virtual objects that can be touched and felt through an 
haptic device, just like visual virtual objects can be seen through a monitor.
Haptics is gaining widespread acceptance as a key part of virtual (or augmented) 
reality systems, adding the sense of touch to previously visual-only solutions. Most 
of these solutions use stylus-based haptic rendering, where the user interfaces to the 
virtual world via a tool or stylus, giving a form of interaction that is realistic and 
computationally affordable on today’s hardware. Examples of successful implemen­
tation of haptic-based computer simulation include tools for the training of surgeons 
who can perform on virual patients or virtual sculpting tools for rapid prototyping.
2.2 Human-computer interactions
Human beings probe their environment via the five senses. Engaging the user’s senses 
is the key to a good human-computer interface. Sight and hearing have traditionally 
been exploited, and touch has recently been added to augmented reality simulations. 
These three senses define three major communication channels (Picture 2.1) between 
mind and CPU. Each channel can be exploited for input to the computer (using 
sensors) or output to the user (using actuators).
•  V isual Channel: This is probabily the most intuitive and widely used one. 
Computers have used monitors since their birth to convey visual feedback, and 
recently cameras and other devices have been employed as visual input devices.
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•  A uditory Channel: The use of speakers to play sounds is not recent. Micro­
phones can also be used as auditory sensors. System sound alerts and game 
sound effects are examples of auditory output. Videogames use surround audio 
systems to help the player locate the position of a virtual object that cannot be 
directly seen.
•  K inesthetic Channel: This channel is linked to the sense of touch. Touch 
screens and even mice are examples of kinesthetic sensors. Haptic feedback is 
a recent application, and is usually provided by a haptic device.
(monitors)
Visual Channel
(cameras)
M ln d  .
Auditory Channel CPU
(microphones) 
(haptic device)
Kinesthetic Channel
(mouse)
Figure 2.1: Human-computer interactions: the three main channels of communication 
between mind and CPU
Multimodal (interacting via more than one sensory channel) virtual environments 
have been demonstrated to convey a better sense of presence and a richer experience 
than single-sensory technologies. It has also been shown that response times of users 
to multisensorial stimuli are significatively shorter than the corresponding stimuli 
alone. Mental processing times of a trimodal signal (haptic, audio and visual) are
15
shorter than those associated to the processing of any bimodal or unimodal signals 
[26].
2.3 Previous applications to  molecular system s
The possibility of using haptic technology to interact with chemical environments or 
simulations has been described before [27]. In previously developed software packages 
like the Chemical Force Feedback system [28] and HAMStER [29] the force feedback 
was successfully applied to different chemical systems (usually interactions between 
small molecules). However the way the problem was tackled in these applications and 
the need for computer power that was not available in the past made their extension 
to larger systems and their applicability to drug design problematic. In particular 
these systems relied on the use of pre-calculated potential grids and, as pointed out by 
Wollacott, this would limit the use of haptics on large biological systems like proteins
[29].
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Chapter 3 
Aim s
Molecular modelling and drug design are creative processes that display several fea­
tures that make them closer to human reasoning than to machine automation. How­
ever, very often the user intervention is limited to the preparation of the input and 
analysis of the output of a computer simulation[30]. In some cases, allowing human 
intervention directly in the process could improve the quality of the results by ap­
plying the researcher intuition directly into the simulation. This project is aimed at 
the implementation of an interactive drug design environment based on haptic tech­
nology and its application alongside more traditional computational approaches to 
several drug design projects in the antiviral and anticancer fields. Besides comparing 
the approaches on general bases the goal is to test the performance of the interactive 
approach on actual research projects and understand if their combination with tradi­
tional approaches can be beneficial in terms of improving the quality of the designed 
s true tines.
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Chapter 4
Im plem entation of a Trimodal 
Feedback Drug Design  
Environm ent
4.1 Zodiac
Zodiac is an open source molecular visualiser (www.zeden.org). It relies on open- 
babel (www.openbabel.org) for molecular files input and output and some chemical 
prediction features, openGL for the 3D rendering and Trolltech’s QT4 for the GUI. 
At the time the present project was started zodiac was able to open a molecular file, 
load the atomic coordinates and display the molecule on the screen. Some options 
to time the graphical output were possible, and bonds could be displayed as lines or 
cylinders, while atoms could be optionally rendered as space-filling CPK spheres.
Besides optimising the code for speed and reliability, zodiac needed the implemen­
tation of a series of visual as well as audio feedbacks along with the addition of the 
haptic code and the minimisation engine.
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4.2 C ore calcu la tion  cycle
A conceptual scheme of the implementation is shown in Figure 4.1. Algorithm 1 
shows the pseudocode for the main calculation cycle.
r ■> >
Calculate atomic <------ Identify H-bonds and
Forces set atomic scores
l j ^ __  J
I  M W  tc
Calculate and save Update atom
resultant force ------► coordinates
v  J  ^ j
| -iOOOHz 
1
t
i\
Apply inverse of view apply view rotation
rotation matrix and scale matrix and scale
- 3 3  Hz
Color atoms, 
calculate H bonds 
and trigger full 
graphic update, audio 
feedback
.
Haptic P en ce
_ _
Figure 4.1: Conceptual scheme of the implementation: the core cycle is shown along 
with the three interaction channels between user and CPU
Inside the molecular environment, a set of atoms (typically a small molecule) are 
defined as a probe (ligand). All the remaining atoms form the environment. The 
molecular scene can be rotated via the use of a virtual trackball. The rotation is 
stored into a matrix. For every frame of the simulation, the movements of the haptic 
device are translated into coordinate shifts of the probe. The inverse of the rotation 
matrix is applied to this translations to make sure that the reference system of the 
probe remains the same as the user’s, despite the rotations of the view. A forcefield
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Algorithm 1 Calculation cycle
UpdateLigandPositionWithHapticPointer () 
ComputeInternaiInteractions() 
for i =  1 to ligandatoms do 
GetNeighbourList (atom*) 
CalculateLigandProteinlnteractions (atom*) 
end for
ComputeTotalForce ()
ApplyForces ()
calculates interactions internal to the probe and between probe and environment 
and sets a force on each atom of the probe accordingly. Each atom of the probe is 
then moved proportionally to its force. The total force on the probe is computed, 
smoothed (see section 4.6), rotated using the view rotation matrix and set on the 
device. Visual and audio feedbacks are also calculated. The total energy of the 
system, the interaction energy and the inner energy of the probe are calculated. If 
the energy values and the coordinates of the atoms satisfy the threshold and clustering 
limits set by the user, the pose is saved in molecular database for further analysis at 
the end of the simulation along with the three corrisponding energy values. The GUI 
features a button for the user to force the saving of a pose he/she likes.
4.3 Visual, auditory and haptic feedback
The resulting force on each of the ligand’s atoms is applied to the user’s hand via 
the haptic device. The user has therefore a direct feedback on the degrees of freedom 
he/she can control (at least for translations. It is theoretically possible to do the 
same for torsions applying torques to the user, but that involves the use of a much 
more expensive device, which hasn’t been used in this project yet). At any moment 
the user can decide to let the simulation evolve or can oppose his/her own force and 
guide it in the direction he/she prefers.
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To improve the experience of the user the visual feedback has also been improved. 
Zodiac is capable of exploiting 3D projection and visualisation devices to give a full 
3D experience. Hydrogen bonds are also detected and marked in real time, and shown 
with lines. The opacity of the line is proportional to the “strength” of the bond (in 
terms of deviation from optimal distance and angle, as defined in chemscore). It is 
therefore possible to see lines fade in and fade out as the corresponding hydrogen 
bonds are formed or broken. Atoms are usually coloured according to their atomic 
number. However it is possible to choose an energy-based colour coding. This will 
colour atoms with different shades of colour according to their predicted interaction 
energy. While the simulation runs atoms will change their shade of colour as they 
move towards a more favoured position, or will turn a different colour if they axe 
forced into a clash or another energy-disfavoured interaction. It is also possible to 
define water accessible surfaces (Connolly surfaces) to define the active site shape, 
and clipping planes that allow to work with ligands in narrow pockets.
Audio feedback is also provided in the form of sound alerts that mark when certain 
favourable conditions set by the user are met. Quantitative information can also be 
encoded in the audio by modulating the volume of a soundtrack.
4.3.1 Implementation of visual feedback 
Backbone
Computing higher-level graphical representations from a set of atom coordinates is 
crucial to outline the 3D organisation of macromolecules. Protein backbone trace is 
a very useful guide in understanding folding and spatial organisation. An adaptation 
of the algorithm described by Pristle[31] has been implemented in Zodiac to calculate 
backbone traces. For each residue of a target protein the midpoint of the two peptidic 
bonds with the preceding and following amino acids are stored in a fist. When an 
amino acid is not forming a peptidic bond, the coordinates of the a  nitrogen or of
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Figure 4.2: Visual feedback: the per-atom color-coded scores are shown, along with 
H-bond depiction and clipping planes
VISUAL
Shape and structures backbone trace, molecular surfaces
H Bonds H bonds highlighting
Scores per atom color coded scores
total energy energy value display
Potential fields potential isosurfaces
3D space and depth stereo display
AUDIO
total energy soundtrack volume
choice of a new good pose sound alert
HAPTIC
total force on the ligand force on the haptic device
Table 4.1: Multisensorial feedback
2 2
the carbon of the a  carboxylic group are used. Intermediate points are interpolated 
between points in the list iteratively using the following approach (see Figure 4.3):
•  The penultimate point from the list of the preceding residue and the second 
point from the list of the following residue are added to the list. If these points 
cannot be found they are extrapolated from the coordinates of the first two and 
last two points of the list respectively. These points are used as guides to make 
sure that the junction between one the backbone line of one residue and the 
following is smooth.
•  For each three consecutive points ABC in the list, two points I and L are 
interpolated, so that A, B, C, I and L all stand on the same circle and the arc 
AI is equal to IB and BL is equal to LC. If A B and C are colinear, then I and 
L are simply the midpoints of AB and BC respectively.
•  If the list has more than four points, between all pairs of points but the first 
pair and the last pair two points will be generated (if the points are A B C D, 
between B and C there will be a point on the circle ABC (II) and one on BCD 
(12)). The midpoint between these two interpolated point is added to the list 
in the appropriate position.
•  the first and last points are removed from the list.
Each cycle generates k — 1 new points where k is the number of points in the list. 
The number of total points is 2n +  1 where n is the number of smoothing cycles. 3 
or 4 cycles are usually sufficient to generate the impression of a continuous curved 
line. The backbone is either rendered as a line connecting each point in the residues 
lists, or as a tube (Figure 4.4). For tube representation for each point in each list a 
“modified circle” is computed with the equation:
X  =  bsin(a) — bcsin3(a)
Y  =  acos(a)
Z =  0
Where the Z axis is aligned along the backbone line and X gives the direction of the
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(a) Four consecutive points in a list A B C D
(b) Circles for ABC and BCD are identified. II and 12 are 
the midpoints of the BC arcs on the two circles.
; 11
' ^  I ^
\ '  \  / v
\  /  \ P /  □'
/  ^  --'"12
' B
(c) P, midpoint of 1112 is added to the list.
(d) Iteration of this process gives a list of points that form 
a smooth line still passing for A B C and D
Figure 4.3: Backbone points interpolation
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C = 0  bond in the backbone, with a  G [0, 2tt[. For Helices and /5-sheets a =  0.3 b =  
1 and c =  0.9 are used by default, to give the impression of a flat ribbon, while for 
loops a =  b =  0.3 and c =  0 yeld a circle (Figure 4.5) a, b and c values for loops, 
a-helices and /5-sheets can be easily customised through the preferences menu.
(a) Line (b) Tube
Figure 4.4: Backbone representations
Surfaces
The perception of the three-dimensional structure of a macromolecule is very difficult 
without the aid of a graphical representation that helps the user understand its shape. 
The implementation of such representations is therefore vital for any molecular mod­
elling software that aims to a successful interaction with the user. The generation of 
two different types of surfaces was implemented in Zodiac for this project:
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(a) loops section: a =  0.3 b =  0.3 c =  0.0
(b) helices and sheets section: a =  0.3 b =  1.0 c =  0.9 
Figure 4.5: Backbone sections
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•  Chem score clash map: This surface is very fast to generate and gives a 
general idea of the shape of a set of atoms. The target molecule is enclosed into 
a grid, with a resolution set by the user, 4 angstrom bigger than the molecule 
in each dimension, on each side. For each node of the grid the chemscore clash 
value of a probe atom is calculated and stored. Tetracoordinate atoms are not 
considered for this calculation, as they should not contribute to the surface for 
geometrical reasons. A Marching Cubes algorithm is then run on the grid with 
a threshold value of 0. For each cube of the grid this routine analyses the 8 
values at the corners. Unless all of them are either bigger or smaller than the 
threshold value, the region where the threshold is met is estimated by means 
of a look-up table, and one or more triangles are computed on the surface that 
splits the cube into a “bigger than threshold” and “smaller than threshold” 
area. The resulting set of triangles from each cube form an isosurface where the 
clash term of chemscore is approximately null, which gives a good idea of the 
shape of the molecule.
•  Solvent accessible surface: Also known as Connolly surface, is more precise 
and delimitates the portion of space that is not accessible to a molecule of 
the solvent (generally water). This is done in two steps. First a grid is built 
similarly to the one used for the chemscore clash maps. On each node of the 
grid the distance from the nearest atom (distance from the center minus the Van 
der Waals radius of the atom) of the molecule is calculated (tetracoordinated 
atoms are not considered). An isosurface of value 1.4 is generated with the 
same marching cubes algorithm described earlier. This surface represents the 
positions of the center of a sphere of radius 1.4 angstrom that is rolled onto 
the molecule. A second isosurface is generated of points that are 1.4 angstroms 
away from the first surface, and less than 1.4 angstroms from an atom of the 
protein.
Each surface can be visualised either come solid (or transparent) surface or as a 
wireframe (Figure 4.6).
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(a) Solid Color (b) Wireframe
(c) alpha = 0.8 (d) alpha = 0.2
Figure 4.6: Surface display modes
2 8
P o ten tia l m aps
Potential maps allow to calculate the potential (energy that a probe atom  would 
have if was placed in a particular region of space). A map can be derived from any 
energy function and is usually rendered by means of one or more isosurfaces. Ju st like 
molecular surfaces, potential isosurfaces can be transparent, solid color or wireframe. 
Lipophilic maps help identify hydrophobic pockets and are useful when working with 
lipophilic ligands or fragments, Hydrogen bond potentials can help direct the  design 
and positioning of hydrogen bond donor or acceptor moieties. Electrostatic maps 
axe useful when working with charged groups and exploring the possibility for the 
formation of salt bridges.
An example of potential map is shown in Figure 4.7
Figure 4.7: Potential maps
M anaging transparency
Transparent surfaces are very useful because they allow the user to see which atom 
is closest to a particular region, which is vital when probing a chemical environment. 
OpenGL uses an RGBA (red green blue alpha) system for the representation of col­
ors. Setting the alpha value to less then 1. and enabling alpha blending allows for
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the display of transparent objects. However, due to the way alpha blending works, 
transparent objects need to be drawn on the screen in the correct order, from the 
furthest away from the screen to the nearest. This order depends not only from the 
coordinates of each object, but also from the rotation of the viewport, and needs to 
be recomputed every time the scene is rotated. To do this in a time-efficient way a 
pigeon hole approach was used in Zodiac. After every non transparent object has 
been drawn, a rapid check among each object flagged as “transparent” is done, to 
find the distances from the screen at which the region containing transparent objects 
starts and ends. This region is sliced into N subregions of fixed width, or NMAX 
subrregions of appropriate width if N is greater than NMAX. Each transparent trian­
gle is assigned to the appropriate region, according to the distance of its center from 
the screen. Each region is then rendered, starting from the furthest away from the 
screen.
Stereo display
The perception of depth is very important when working with a three-dimensional 
environment such as a molecular modelling simulation. To convey the impression 
of the third dimension on a bidimensional surface such as a monitor or a projection 
screen it is necessary to bring two different images on each eye. One popular way 
to do this is using different fight for the two images (different polarisation is often 
used). Special glasses are worn that can block one of the two images on each eye. 
The two images can be projected on the same screen or can be composed into an 
interlaced image where odd and even rows (or columns) of pixels originate from the 
two different sources.
To exploit 3D system the graphic scene needs to be rendered twice. The scene 
for the left eye is rendered by translating the camera to the left and rotating slightly 
to the right, and the opposite is done for the right eye. For stereo-enabled graphic 
cards (such as the NVIDIA Quadro series) four buffers are used (back and front left, 
back and front right). The two different scenes are drawn on the left and right back 
buffers. For interlaced stereo systems, a single image needs to be constructed. With
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the use of the stencil buffer first alternated rows (or columns) are filled with one of 
the pictures, then the remaining rows (or columns) are filled with the other.
4.3.2 Implementation of auditory feedback
While the user is engaged in the simulation the total energy of the complex is printed 
out on screen. Following this number as it changes over time can be distracting 
because the user is forced to look away from the molecule he/she is working with and 
also keeping track of the changes of a nuber that is updated 30 times a second is not 
an easy task. To help convey the energy information in a more natural way two kinds 
of auditory feedback has been implemented.
In the first one a simple sound alert is played whenever a new pose is saved (see 
chapter 4). This gives direct information about if a particular region of the binding 
pocket is yielding good results.
The second one provides more precise information about the absolute value of the 
interaction energy and his variation over time. The user selects one or more audio 
files (.mp3 .wav and any other format that is supported by the underlying system is 
accepted) to be used as a soundtrack. The files are played one after the other while 
the simulation runs, and the volume is finked to the relative value of the interaction 
energy with respect to the highest interaction value found up to that moment (See 
Equation 4.1).
volume =  <
E h t > -{-to le ra n ce-E  
1 ( J  to le ra n ce
lo
“IfE ^ Ebest
ifE  > Efest +  tolerance
ifEbest < E < Ebest +  tolerance
(4.1)
Where volume =  0 is no sound and volume =  1 is the loudest volume the current 
settings of the underlying operative system can output. The exponential function
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allows for bigger changes in volume when the energy is close to the best one observed.
4.3.3 Implementation of haptic feedback
The setting of the feedback force on the user hand is highly dependent on the device 
and the haptic library that are being used. When the value for a new force vector 
is generated from the computation cycle, it is stored in a variable. The haptic code 
that is responsible for the actual setting of the force to the device runs on a separate 
looping thread, using each time the latest available value for the force. This allows 
for a smoother feedback (see chapter 4.7) and an easier implementation of different 
haptics libraries. Three different haptic libraries have been implemented:
•  gH aptics is the library provided by Novint. It is compatible with the Falcon 
device only, and only available for windows.
•  O penH aptics is developed by SensAble. It is cross-platform and supports the 
whole range of sensable devices.
•  H API is an open source library, part of the H3DAPI library, developed and 
distributed by senseGraphics. It acts as a layer between the code and a series of 
different proprietary libraries, including gHaptics and Ghost (another of sens- 
able’s SDKs). It is therefore able to drive Novint and Sensable devices among 
many others.
4.4 D egrees o f freedom
The number of degrees of freedom of a problem is the minimum number of indepen­
dent variables that are necessary for its mathematical description. The scoring of the 
interaction of a single rigid molecular fragment and a receptor depends on six param­
eters (three coordinates for the translational vector and three angles for rotations to 
position the ligand with respect to the protein). Accounting for internal flexibility of
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ligand and protein results in a higher number of degrees of freedom.
In this application two different models were implemented:
6 DoF m odel
This is the simplest possible model. Both the ligand and the protein are considered 
as rigid bodies. This simplification allows not only to reduce the number of degrees 
of freedom to 6, but also allows the internal energy of ligand and protein to be 
considered constant during binding, thus reducing the computation of the binding 
energy to the determination of the interaction energy alone, neglecting the change in 
the internal energy in the binding partners. The main drawback of this type of model 
is that binding affinity is highly conformation-dependent and molecules in general 
simply cannot be considered completely rigid. This approach, though, is still useful 
in fragment-based methods, as molecular fragment such as fused aromatic rings or 
carboxylic groups can be treated succesfully as rigid entities.
Y translation
_ XZ rotation
X translation
YZ rotation
XY rotation
Figure 4.8: 6 degrees of freedom model
3N DoF m odel
This is the most accurate possible model. Each atom of the system is allowed to
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move freely (the number of degrees of freedom is three times the number of atoms, 
as each of the three cartesian coordinates of each atom is independent from the 
others). This way though, internal energies cannot assumed to be constant any more, 
and contribution such as bond stretchings energy or bond torsion energies must be 
computed. This is the way molecular systems are usually treated during energy 
minimisation and in molecular dynamics simulations.
Figure 4.9: 3N degrees of freedom model
A third model is possible:
6+ r DoF model
This is an intermediate approach between the two previous models. Bond lengths 
and angles are assumed to be constant, while rotations around single bonds (usually 
only for ligand rotatable bonds) are allowed. This brings the number of degrees of 
freedom to six plus the number of rotatable bonds in the system. The computation of 
internal energies can be simplified, since the contribution from bond stretchings and 
angle bendings are constant. Other terms such as torsional energies of the rotatable 
bonds must still be computed. This model is the one most docking programs imple­
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ment as the simplification of fixing bonds stretching and bendings is a slight one and 
allows for a drastic increase in the speed of the algorithm. A drawback of this sort of 
model is that it is more difficult to implement, as it requires a kinematic chain to be 
built for the molecule and inverse kinematics application to have it correctly respond 
to an outer force, which in the particular case of this implementation would render it 
probably slower than the previous, more precise one.
Y translation
XZ rotation
Portion 3|
X translation
Torsion I
XY rotation
Z translation
Figure 4.10: 6+r degrees of freedom model
4.5 M inim isation
Depending on the type of haptic device, the user is able to directly control 3 or 6 
degrees of freedom. As the model has at least 6, and usually more, it is necessary to 
find a way to control the others. A double input such as haptic-keyboard or haptic- 
mouse could be used in the 6 dof model, but it is clearly impossible to let the user 
control all the degrees of freedom in an interactive way in a more accurate model. 
Energy refinement techniques have been employed to overcome this problem. Three
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or six “major” degrees of freedom (the three components of the translation vector and 
optionally the three rotation angles applied to the ligand) are linked to the haptic 
pointer position, and are therefore controlled directly by the user, while the CPU 
controls the others. A steepest descent-like method was chosen, computing at each 
step the first derivative of the energy with respect to each degree of freedom and taking 
for each a step proportional to the opposite of the derivative. Usually in molecular 
mechanics m inim isations these steps are biased to improve the speed of the algorithm 
in finding the local minimum. In this application however minimisation does not have 
to be too fast because otherwise it would appear unnatural. The goal is achieving a 
system capable of reacting at the user’s inputs in realtime, slowly enough to let him 
or her the time to understand in which direction it is evolving and have an idea of the 
energy landscape in a particular region. Physically, our minimisation is equal to the 
system moving with a speed proportional to the force to which it is subjected. It is 
import to point out that this is not molecular dynamics. Dynamics employs Newton’s 
law of motion, in which a force causes an acceleration. In molecular dynamics concepts 
like kinetic energy and inertial forces have a significance and allows to simulate the 
actual movement of molecules. In this implementation the system evolves according 
to Aristotle’s laws of motion, which states that a force causes a velocity. Therefore 
an atom in motion subjeted to no force will stop its motion immediately, as opposed 
as continuing with constant speed.
4.6 V iscous forces
The calibration of the scaling constants that translate predicted forces to the actual 
one that is applied to the user is not trivial. The parameters to take into account are 
different and sometimes difficult to evaluate: if the force is not strong enough the user 
might not feel the weaker interactions, and is also allowed to move atoms in closer 
proximity, where the van der waals function is steeper and therefore more difficult 
to control, making the simulation unstable. If, on the other hand, the force is too 
strong it might damage the device, and makes it difficult for the user to control the
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simulation (which will converge to the closest strong interaction, such as a salt bridge, 
and trap the device there). The size of the virtual working space is also important. 
The haptic working space is mapped to a cube in the virtual space. If this cube is too 
big, a small change in the device’s position will result in a big change in the ligand’s 
coordinates, and therefore a big change in its environment and an unexpected change 
in the force applied to the device. This in turn will cause an even bigger movement 
of the user’s hand and start a vicious circle. If on the other hand the mapped space 
is too small it becomes hard to explore the binding site effectively. One problem that 
often arised during the parameterisation was the interaction with narrow pockets. If 
the clash with one wall of the pocket is strong enough to send the ligand to clash 
with the opposite one before the user has time to react and oppose his force to stop 
the motion, the ligand will likely start to bounce from one end to the other, even if 
the space in the middle is big enough to host it. Besides reducing the virtual working 
space and increasing the force scaling constant, a “viscous force approach” was used. 
This consists in considering not only the present value, but also the recent past ones 
when the force is calculated. Whenever a new value for the total force is obtained, it 
is pushed into a queue. If the size of the queue is bigger than a fixed value, the least 
recent value is popped out and the force to apply is then calculated from the mean of 
all the values in the queue. This allow for forces to change more gradually and lets 
the user more time to react to sudden changes (Figure 4.11). Another approach has 
been implemented, which does not require a queue and is faster. The force applied to 
the device is computed as shown in Equation 4.2, where Fiast is the last force that 
has been set oh the device and Fnew is the latest computed force.
F =  (1 — K ) * Fiast +  K  * Fnew (4.2)
4.7 Asynchronous m ultithreading
In order to be perceived as continuous a set of haptic stimuli needs a very high fre­
quency of update (around lKHz as opposed to 30Hz for visual stimuli). This is due
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Figure 4.11: Viscous Forces: black continuous line derives from black dashed line with 
random noise. Red line represents the corrisponding values of the queue approach 
(size of the queue = 1 0 ) ,  blue line refers to the values of the second algorithm (K =  
10)
to the fact that the sense of touch is far more efficient than sight in distinguishing 
two separate impulses. This high requirement is traditionally a challange in haptic 
programming, requiring the calculations of the force to be carried out in less then 
one millisecond for each update. In the present implementation the task of com­
puting all the atomic interactions involved in molecular recognition and setting the 
corrisponding forces in this time window appeared impossible on a single processor. 
The solution that was adopted involves the use of asynchronous threads. The main 
thread computes the interactions, setting the forces on each atom and moving them 
accordingly. Every 30 ms a visual update is triggered on a second thread. This as­
sures that the the video output looks smooth, avoiding useless computations. A third 
thread is exclusively dedicated to the haptic feedback, feeding the device with the 
latest data computed by the main thread. This allows the haptic feedback to feel 
smooth even when the complexity of the system slows the computation thread below 
1kHz. Since the time required by the haptic thread computation is independent of 
the number of atoms, the haptic update should continue to be adequate even with 
complex systems.
4.8 Im plem entation of the forcefield
A molecular mechanics environment is characterised by one (or more) set of equations 
that describe how it behaves and evolves. This sets of equations are called forcefields. 
Many different forcefields have been developed and described in the literature, each 
one representing a simplification of the laws of physics and chemistry aimed to the 
reproduction of particular molecular characteristcs. The forcefield chosen for the 
Molecular Mechanics environment is MMFF94s.
MMFF94 is one of the most frequently-used force fields in molecular mechanics. 
Developed by Thomas Halgren at Merck ([32, 33, 34, 35, 36]), it is an all-atom general- 
purpose force field, meaning that its parameterisation is meant to account for its 
application to both small molecules and biomacromolecules. Its s (static) version has 
slightly modified parameters that are meant to reproduce “averaged” conformations. 
The main difference is in the conformation of the nitrogen in amines, which should be 
tetragonal but is characterised by a low inversion barrier, and is therefore considered 
to be planar (average between the two opposite conformations). The general equation 
for the energy calculation is made up of seven components (Equation 4.3). The first 
five are bonded contributions, and are used in intramolecolar energy calculations, 
while the last two correspond to nonbonded interactions, and are applied to both 
inter and intramolecular calculations alike.
All the equations are parameterised to give energy predictions in kCal.
£  =  E  EBii+52 EAijk+ '£  EB A jk + T , EOOPijk;l+J2 E vdW u+E  EQtj
(4.3)
STRETCHING ENERGY
EBij (Equation 4.4) is the energy associated with the stretching of the bond be­
tween atoms i and j .  It is calculated with a quartic function from Ary, the deviation 
of the interatomic distance from a reference value (depending in turn on the two atom 
types).
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Figure 4.12: MMFF: Bond stretching function
EBij =  1 4 3 . 9 3 2 5 ^ 1  +  csAr^ +  ^ c s 2A r ? (4.4)
kbij is a constant that depends on the atom types involved in the bond, while cs 
(cubic strenght) is a constant value.
BENDING  ENERGY
iiii
i
E A ij t  =  0 . 0 4 2 8 4 4 ( l  +  cb&D?jk)
\  J
Figure 4.13: MMFF: Angle bending function
EAijk This term refers to the energy associated with binding angle bendings 
(Equation 4.5).
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EAijk =  0 .042844^ p M%k ( l  +  cbM%k) (4.5)
where is the difference between the angle formed from atoms ijk  and a
reference value, ka,ijk is the force constant depending on the atom types involved and 
cb a constant term.
STRETCH -BEND INTERACTIONS
E B A ijk =  2 .51210 (kba.ijk& ri j  +  kbakjiA r kj )  A i%jk
Figure 4.14: MMFF: Stretching-bending function
This term (Equation 4.6) relates the stretching of two bonds that share an atom 
j  to the angle they form.
EBAijk =  2.51210 (hbdijkArij +  kbakjiA rkj) A (4.6) 
OUT OF PLANE BEND IN G  ENERGY
This term (Equation 4.7) is used for penalising non-planar tricoordinate atoms 
(like aromatic carbons for instance).
EOOPi]k,t =  0 .0 4 3 8 4 4 ^ ^ 4 * ; , (4.7)
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EOOPijk,i = 0.043844^ ^ * ^
\  /
Whons angle
Figure 4.15: MMFF: Out of plane bending function
Xijk;i is the Wilson angle between j  — I bond and i — j  — k plane. 
TORSIONAL ENERGY
ETijk i =  0.5  (V5 (1 +  cos®) +  V2  (1 — cos2&) +  V% (1 •+• cos3&)',
\
torsion dtedral
Figure 4.16: MMFF: Torsional energy function
This term estimates the energy associated with torsion around bonds. It exploits 
an empiric periodic equation of the dihedral angle defined by four atoms bound to 
one another to estimate the torsional contribution of the bond between central two 
(Equation 4.8). The three constants Vi, V2, V3 depend on the atom types of the four
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atoms.
ETm  = 0.5 (Vi (1 + cos$) +  V2 (1 -  cos2$) +  V3(1 + cos3$)) (4.8)
VAN DER WAALS ENERGY
E vd iV
Figure 4.17: MMFF: Van der Waals interaction function
The equation that computes Van der Waals interactions is usually made up of 
two parts: an attractive and a repulsive one, both depending on negative powers of 
the interatomic distance (generally -14,-7 -12,-6 or -8,-4). The difference between the 
two exponents causes the repulsive component to prevail at short distances, while as 
the interatomic distance increases the attractive component becomes stronger. An 
equation of this kind is named Leonnar d- J ones equation. In MMFF the Van der Waals 
term is computed with the -14/-7 Leonnard-Jones-like function (Equation 4.9).
E v d W = S ( - ' ™ R»- ) 7 (  U 2Jf f  2)  (4 9)
*J +  U «  +  0.12i?*J )  ( '
ELECTROSTATIC INTERACTIONS
The electrostatic interaction between two atoms is computed with a Coulomb-like 
equation (Equation 4.10). 5 is a small positive constant, that avoids an infinite result 
when the interatomic distance becomes 0.
£ « « - 332'°7“ D ( f V j )  (41°>
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332.0716
Figure 4.18: MMFF: Electrostatic interaction function
4.9 Im plem entation o f the scoring functions
MMFF functions are not optimised to reproduce interaction energies in implicit- 
solvent approaches like the one reported here. Hydrogen bonds are considered non- 
directiona! and electrostatic in nature, and some of the main interactions that are 
considered to drive ligand-protein binding, such as hydrophobic interactions, are not 
considered. For these reasons a hybrid model was built, which exploits both MMFF 
and an empirical scoring function, in addition to the purely force field based one. 
In this model bonded and nonbonded energy contributions internal to the ligand are 
computed by MMFF, while nonbonded interaction energies between the ligand and 
the target are estimated with an empirical scoring function. A large number of scoring 
functions have been developed for docking purposes, differing for parametrisation 
and complexity. Two of the most widely used empirical scoring functions (PLP and 
Chemscore) were implemented in the software.
4.9.1 PLP
PLP [37] (Piecewise Linear Potential) is an extremely simple function. It is a heavy- 
atom-only function (hydrogen atoms are not considered). Heavy atoms are assigned 
one of the following atom types:
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Donor A cceptor Both Non polar
Donor Repulsive H-bond H-bond Steric
Acceptor H-bond Repulsive H-bond Steric
B oth H-bond H-bond H-bond Steric
Nonpolar Steric Steric Steric Steric
Table 4.2: PLP interaction types
• H-bond Donor
• H-bond Acceptor
• H-bond Donor/Acceptor
• Nonpolar atom
An interaction type is assigned to each protein-ligand atom couple according to 
Table 4.2.
The intensity of the interaction is computed with the simple function shown in 
Figure 4.19.
I©UT
CD
CUi
E
Figure 4.19: PLP energy function
A, B, C, D, E and F parameters for each interaction type are shown in Table 4.3. 
A, B, C and D value are expressed in Angstrom, E and F in kcal/mol.
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A B C D E F
H-bond 2.3 2.6 3.1 3.4 -2.0 15.0
Steric 0.93 ri+ r2 1.25 B 1.5B -0.4 15.0
Repulsion 3.4 - - 0.0 15.0
Table 4.3: PLP parameters for the energy function
4.9.2 Chemscore
Chemscore is an all-atom scoring function [38]. We implemented its version optimised 
for docking as described in [16]. The interaction energy in the binding of a ligand to 
a protein is estimated with Equation 4.11:
AGbinding ~  AGhJbond^ hbond. “I" AGmetalSmetal ~t~ AGU p o Slipo Edastx (4.11)
where Shbond> Smetai and Supo terms all make use of a block function, f, described 
in Equation 4.12
1 x  <  X\
(x2 -  x)f (x, x !,X2) =  < Xi < x < x2 (4-12)(x2 -  Xi)
0 x > x2
where x is a running variable, and X\ and x2 are constants controlling the fall-off of f. 
The hydrogen-bond term is calculated for each complementary combination of donor 
and acceptor on ligand and protein. It consists of a distance and an angle-dependent 
part (Eqation 4.13).
Shbond =  ?'DAf{ArDA, Ari, Ar2)f(A a DA, A au A a2) (4.13)
with ArDA =  \rDA~ro\ and Aaz>A =  \qlda~ «o|, where tda is H bond distance and 
ex.da the H bond angle (D-H A angle), ro and Oo are the ideal hydrogen bond distance 
and angle. The metal (Equation 4.14) and lipo (Equation 4.15) terms share the same
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functional form and both depend on the interatomic distance of the metal-acceptor 
or nonpolar-nonpolar pair.
Sm eta l ^ M A f  ( r  MA i ^Vn,! j I'm ,2) (4.14)
(4.15)
The clash term (Equation 4.16) is summed over all non-hydrogen protein-ligand 
atom pairs.
E d a sh  —  ^ ^ d a sh (r  •> Tclash) (4.16)
where r is the interatomic distance and rdash the clash distance. The clash energy 
for each atom pair depends on the nature of the protein and ligand atom; it is 0 for 
r > rdash, and for r <  rdash gets the value shown in Equation 4.17:
e(r, rdash) =  <
20 (rd a sh  t )
A G h bond rdash
20 (rdash 0
A G m e ta l rdash
donor-acceptor pairs 
metal-acceptor pairs (4.17)
1 +  4 (rdash— '[I gjj other non-H pairs
T clash
4.10 H aptic devices
The market of haptic devices has until recently been a very small and specialised 
one. Haptic devices have therefore traditionally been expensive tools. In the recent 
past, however, hardware companies have started to release low-end devices aimed 
particularly to enhance video game experience. The implementation of this project 
was started on such a device, the Novint Falcon, and was then extended to use a more 
professional device, SensAble’s Phantom Omni.
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4.10.1 Novint Falcon
Novint Technologies first released the Falcon (Figure 4.20 ) device in 2006. It is a 
USB device with a ping pong ball-sized spherical grip, connected via three arms to 
a weighted base. The base contains sensors and motors attached to each arm. The 
sensors can triangulate the coordinates of the grip in space, and the motors can act 
together to apply a force to it with desired direction and intensity. The grip can only 
be translated in space, but not rotated. The Falcon is therefore a three degrees of 
freedom (3-DoF) device. Novint also released a software developing kit and drivers for 
the device. Both are windows-specific, and, according to Novint’s developer center, 
support for other operative systems is not scheduled at the moment. Nevertheless 
there are unofficial open source projects for the development of falcon’s drivers for 
linux and macosx.
Figure 4.20: Novint falcon device
4.10.2 SensAble Phantom  Omni
SensAble Technologies is the leader in 3D Touch force-feedback technology. The 
Phantom Omni (Figure 4.21 ) is the most affordable of a wide range of devices, that
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differ for precision, maximum appliable force intensity and size of workspace. The grip 
is a pen-shaped stylus, attached via a segmented arm to the base. There is a range 
of sensors capable of reconstructing the position and the orientation of the pen in 3D 
space (six degrees of freedom). The motors can apply a directional force, but not a 
torque (3-DoF force feedback). Data are transferred to the computer via FireWire. 
SensAble supports Windows, Linux and MacOsX, releasing versions of the drivers 
and the SDK for each platform. However the linux driver is outdated, not supported 
on 64 bit systems nor on the newer versions of the linux kernel. Likewise, the Mac 
version is compiled for PowerPC processors and therefore runs slower on the new Intel 
Macs. The OpenHaptics library (one of Sensable’s SDKs, which despite its name is 
not open source) is compatible with the whole range of Sensable’s haptics. Therefore 
the same implementation should be able to be driven with more professional SensAble 
tools.
Figure 4.21: Sensable phantom omni device
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4.10.3 Nintendo Wii Remote
Nintendo has recently released a gaming console (Nintendo Wii) based on a new idea 
of ergonomic controllers. Instead of the traditional joystick input, the console tracks 
the position of the controllers (Figure 4.22 ) as they are moved in space. Interestingly 
all the technology that allows this resides in the controller itself. Each controller is 
equipped with a 3-axis accelerometer, that is able to track the direction of the force 
applied to the device. When the device is kept still it can track gravity, and therefore 
calculate its orientation. The accelerometer alone is unable to track rotations along 
horizontal planes, because they don’t change the relative position of the gravity vector. 
Therefore the controller also features an infra-red camera. By using 2 sources of 
infra-red light (IR LEDs are the first choice, but normal candles are excellent IR 
light sources as well) it is possible to track this rotations and also the distance of the 
device from the sources. The camera can detect up to 4 infra-red signals. By using 
four infra-red sources with different intensity it is theoretically possible to derive the 
position and the orientation of the device using the camera alone. The Wii Remote is 
obviously not designed to work on a computer, but exploiting a bug in a videogame 
various drivers have been reverse-engineered and allow the exchange of data between 
the device and a computer via Bluetooth. The Wii Remote is equipped with a rumble 
pack. Tuning the frequency of the rumbling and exploiting a tactile illusion it is 
possible to have a pseudo-directional haptic feedback from it.
4.11 Speed measurements
Speed tests were carried out under Microsoft Windows XP Professional 64 bit on 
a Viglen Genie featuring an Intel Xeon E5335 processor, 2 Gb RAM memory and 
ATI RADEON X1550 and under Ubuntu Feisty Fawn 64 bit on a Mac Pro 2.66 GHz 
featuring two Dual-Core Intel Xeon processors, 2 Gb RAM memory and a NVIDIA 
GeForce 7300 GT (256MB) graphic card. As a model of fragment based drug design 
the interactions of quinazoline with the protein kinase A active site (PDB code 1Q8U)
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Figure 4.22: Nintendo Wii Remote
were modelled. W ith water and any non-protein atoms removed and hydrogen atoms 
added, the protein system counts as many as 5051 atoms. Quinazoline is a rigid 
fused ring system of 16 atoms. The speed of the simulation depends on the relative 
position of the fragment to the protein, and has its minimum when the fragment 
is inside the ATP binding cleft, surrounded by protein atoms. The haptic update 
constantly remained above lKHz, while the computation thread update remained 
over 200 Hz for the fully flexible model.
4.12 F u tu re  developm ent: p ro te in  flexibility
The current implementation, similarly to most docking approaches used at present, 
treats the target macromolecule as a rigid body, and just explores the flexibility of the 
ligand (semi-flexible approach). While this is often accepted as a reasonable simplifi­
cation, it is true that many software companies are moving towards the inclusion of 
protein flexibility exploration (fully-flexible approach) in molecular docking simula­
tions. This has been done to different degrees, from the simple exploration of rotamers
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of predefined amino acid side chains to the prediction of backbone flexibility using 
short molecular dynamics runs. Similar approaches could be used to include protein 
flexibility into the haptic-driven simulation. Atoms of the side chains of preselected 
residues could be treated in the same way as the atoms of the ligand, allowing them 
to move freely, and constraining the position of the a  carbon. Simulations of this 
kind has been shown to produce an high number of unrealistic conformations, so it 
would be probabily be necessary to restrain the original coordinates of the atoms to a 
certain extent. Theoretically the same principle can be extended to backbone atoms. 
The complexity of the system however increases combinatorially with the number of 
ligand atoms, and therefore this method would probabily not be effective for more 
than a few flexible side chains without rewriting the core of the computation. One 
possible way to gain computational power would be the parallelisation of the compu­
tation code, that would allow to effectively exploit clusters of CPUs or even GPUs. 
Another feasable approach would be the use of libraries of rotamers. Before the sim­
ulation is started libraries of low energy rotamers could be calculated for each amino 
acid. While it is running a separate looping thread could pick random amino acids 
and check if one of the rotamers from its library would have a lower energy and if 
that is the case set that conformation as the current one. It would be also possible 
to allow for fully flexible proteins by using a simplified force field similar to the ones 
used for molecular dynamics. The whole protein would be allowed to evolve in a 
solvent-implicit dynamics simulation, while the ligand and its interactions with the 
protein would be treated by a more precise forcefield. The minimisation of the protein 
wouldn’t need to be as fast as it is now, because it is not involved in the generation of 
haptic feedback. Since protein atoms would no longer be fixed in space (characteristic 
on which neighbours fists currently rely) minor changes would be necessary to the 
neighbours fist generation algorithm to account for that. Apart from this the force 
generation code should rim exactly as it is, as long as the access to protein atoms 
coordinates and forces are made thread-safe (which should be the case as soon as the 
code is parallelised).
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C hapter 5
D esign of A nticancer Drugs 
Targetting th e EG FR  Pathway
5.1 EGFR
EGFR (epidermal growth factor receptor) is the best-studied member of the HER 
(human epidermal growth factor receptor) family. Some EGFR inhibitors are already 
on the market as anticancer drugs[39, 40, 41, 42, 43]. The aim of this section was 
to use various modelling techniques for an in silico characterisation of the binding 
modes of some current drugs to use for the developement of new scaffolds for EGFR 
inhibitors. Various molecular modelling techniques were combined to design lead 
molecules for in vitro testing.
5.1.1 Eukaryotic protein kinases
Eukaryotic Protein Kinases (EPKs) are a class of enzymes that catalyse the transfer 
of a phosphate group from a donor nucleotide (ATP or GTP) onto a peptidic sub­
strate. This reaction (named phosphorylation) is the most frequent and well-studied 
post-translational protein modification in vivo and is opposed to dephosphorylation
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(catalysed by protein phosphatases) [44]. The balance between phosphorylation and 
dephosphorylation (Figure 5.1) of target proteins has proven to be a key mechanism 
in the regulation of several cellular processes, such as cell cycle progression, growth 
and apoptosis. For this and other reasons kinases are currently the second most 
im portant target in pharmacological therapy [45] after GPCRs.
serine, 
threonine, 
or tyrosine 
side dhain
PROTEIN KINASE
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■ p r o t e i n  p h o s p h a t a s e  -* *  P h o sp h o r y  la te d
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Figure 5.1: Phosphorylation and dephosphorylation
The human kinome [46, 47] counts more than 500 members, divided into seven 
subfamilies. The map of the human kinome is shown in Figure 5.2. According to the 
their substrate specificity EPKs are classified into two major groups:
• Ser-Thr kinases transfer the phosphate onto an aliphatic hydroxyl group (ser­
ine and threonine side chains)
• Tyr kinases target an aromatic hydroxyl group (tyrosine side chain)
Tyr kinases can be both solubile enzymes (non-receptor tyrosine kinases or NRTKs) 
or membrane-bound receptors (receptor tyrosine kinases or RTKs).
5.1.2 RTKs
RTKs are transmembrane proteins. They consist of 3 superdomains: a transm em ­
brane region and one on each side of the membrane. The extracellular portion presents
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Figure 5.2: Map of Human Kinome (http://kinase.com /hum an/kinom e)
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a ligand-binding domain and an extracellular juxtamembrane region connecting it to 
the transmembrane domain. The intracellar portion is divided into intracellular jux- 
tamembrain region, kinase domain and a flexible C-term tail.
When a growth factor acts upon a specific cell surface receptor harboring a tyrosine 
kinase activity, cell fate decisions are affected through a complex succession of sig­
nalling events. The large family of growth factor receptor tyrosine kinases may be 
considered as allosteric enzymes, whose regulatory portion binds the allosteric reg­
ulator, a ligand growth factor of relatively low molecular weight, and consequently 
undergoes large-scale conformational changes leading to receptor dimerisation. As a 
result, the catalytic kinase portion, which faces the intracellular milieu, undergoes ac­
tivation and transfers phosphate groups to the tyrosine residues of nearby molecules, 
including dimer partners and substrate proteins participating in signal transfer [48].
5.1.3 The HER family
Among all RTKs, the HER (ErbB) family (also called the type I RTKs) is considered 
the prototypic founder sub-group of the RTK super-family, which includes 18 other 
small sub-groups of related receptors.
Two out of the four HER proteins, namely HER-1 (also called epidermal growth 
factor receptor; EGFR) and HER-4, are autonomous; when bound by a ligand growth 
factor they undergo dimerisation and generate intracellular signals culminating in 
cell proliferation, migration or differentiation. The other two receptors are non- 
autonomous: HER2 (also called HER2 in human and Neu in rodents) binds no sol­
uble ligand, but acts as .a preferred partner in heterodimeric complexes with other, 
ligand-bound HERs. On the other hand, HER-3 cannot generate signals in isolation 
because the kinase function of this receptor is impaired. Nevertheless, in the context 
of a heterodimer, primarily with HER2, HER3 can mount potent intracellular signals. 
Interestingly, HER1, -3 and -4 can each bind several distinct ligand molecules, which, 
according to genetic evidence, are partially redundant in their function. [49]
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5.1.4 Structure of the kinase domain
Kinase domains of the EPKs are highly conserved in sequence and structure. They 
fold into a a bilobate structure, the N-term portion forming a lighter lobe (N-lobe) and 
the C-term portion forming a heavier subdomain, called C-lobe. The motif connecting 
the two subdomains is named hinge region (Figure 5.3).
The N-lobe is folded mainly in antiparallel /5-sheets, with the only exception of 
a conserved a-helix (a-C helix). The C-lobe is composed of several a-helices. Other 
important motifs are the Gly-rich loop (or phosphate-binding loop or P-loop) and the 
catalytic loop.
ATP binds in a deep cleft between the two lobes, the phosphate tail forms several 
interactions with the Gly-rich loop and other conserved amino acids, and the 7- 
phosphate is positioned near the catalytic aspartate residue on the catalytic loop 
(Figure 5.4). The peptidic substrate positions itself in a pocket between the activation 
loop and the C-a helix.
5.1.5 HER kinases activation
The HER family of receptors activate a multi-layered network mediating crucial path­
ways leading to cell proliferation, differentiation, migration and altered metabolism 
(Figure 5.5), in response to activation of the receptor by the epidermal growth fac­
tor (EGF), transforming growth factor-a (TGF-a), and several other related peptide 
growth factors.
Activation of the ligand-binding domain by the extracellular ligand leads to ho- 
modimerisation or heterodimerisation among the members of the HER family. The 
structural basis for ligand-induced dimerisation of the extracellular region of EGFR 
family members is now well understood [51, 50]. This dimerisation (Figure 5.6) results 
in the phosphorylation of tyrosine residues in the C-terminai tail segments, which 
serve as docking sites for signaling molecules that contain SH2 or PTB (phospho- 
tyrosine binding) domains and are responsible for onward transmission of the signal
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Figure 5.3: Structure of kinase domain
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Figure 5.4: ATP binding pose
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Figure 5.5: EGFR signalling pathway[50]
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[52]. EGFR, HER2, and HER4 contain catalytically competent kinase domains and 
can form heterodimeric pairs with each other. HER3 contains an inactive kinase 
domain, but it can pair with and activate the other members of the family.
a
Figure 5.6: EGFR dimerisation[50]
Structural events taking place in the intracellular region after extracellular dimeri­
sation and resulting in kinase domain activation axe much less clear. It has been found 
that the EGFR kinase domain can be activated by increasing its local concentration or 
by mutating a leucine (L834R) in the activation loop, the phosphorylation of which 
is not required for activation. The crystal structure of the EGFR tyrosine kinase 
domain was first published in 2002 both alone and in complex with an inhibitor (er- 
lotinib) [53], and displayed several unique features. While structural studies of the 
kinase domains from other RTKs (and protein kinases in general) have shown them 
to be catalytically inactive until an activation event such as ligand-induced dimeri­
sation causes them to become autophosphorylated within the activation loop and
6 0
subsequently become locked into a characteristic active comformation, members of 
the EGFR family appear to be unique in not requiring activation loop phosphory­
lation for their activity. The crystal structure of an unphosphorylated form of the 
EGFR kinase domain was found to be constitutively locked in the active configura­
tion. In a recent study [54], it is suggested that the kinase domain of the EGFR is 
regulated by a direct allosteric stabilisation of the active conformation. This suggests 
that the kinase domain is intrinsically autoinhibited, and an intermolecular interac­
tion promotes its activation. Using further mutational analysis and crystallography it 
was demonstrated that the autoinhibited conformation of the EGFR kinase domain 
resembles that of Src kinases [55] and cyclin-dependent kinases (CDKs) [56].
EGFR activation results from the formation of an asymmetric dimer (Figure 5.7) 
in which the C-terminal lobe of one kinase domain plays a role analogous to that of 
cyclin in activated CDK/cyclin complexes. The CDK/cyclin-like complex formed by 
two kinase domains thus explains the activation of EGFR-family receptors by homo- 
or heterodimerization. An activating heterozygous mutation in the activation loop 
of the kinase domain of EGFR, L834R (also identified as Leu858 in an alternative 
numbering of the human EGFR sequence), has been found frequently in lung cancer 
patients (accounting for 41% of EGFR mutations in these cancers [57, 58]). An ad­
jacent leucine residue (Leu837) is mutated to glutamine in some lung cancer patients 
[59]. These residues are either partially (Leu834) or completely (Leu837) surface 
exposed and do not play an obvious structural role in the active conformation. In 
contrast, the importance of these two residues is obvious upon consideration of the 
Src/CDK-like inactive conformation because both residues pack against hydropho­
bic sidechains in the interior of the kinase domain. Replacement of either leucine 
by a polar sidechain is likely to destabilise the Src-like inactive conformation and 
thereby activate the kinase domain. Interestingly, Erlotinib is incompatible with the 
Src/CDK-like inactive conformation, which may explain why activating mutations 
potentiate the effectiveness of the closely related drug Gefitinib [57, 58].
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Figure 5.7: EGFR kinase domain asymmetric dimer
6 2
5.1.6 Anti-EGFR therapies in clinical use
Current anti-EGFR chemotherapy follows two main approaches: tyrosine kinase in­
hibitors (TKIs) and monoclonal antibodies (mABs). Both classes have reached an 
advanced stage of clinical developement and each approach has its strengths and 
weaknesses.
• TKIs: Tyrosine kinase inhibitors are a class of small molecule drugs that com­
pete with ATP for the binding to a tyrosine kinase active site. There are several 
example of this class of compounds among EGFR inhibitors currently on mar­
ket or in advanced clinical trial. The major problem of this class of drugs 
is selectivity. There are about 518 known protein kinases in the human pro- 
teome [46] and all of them share a higly conserved ATP-binding pocket. It has 
been proven that kinase inhibitors can cross-inhibit even loosely related kinases, 
making selectivity a real challenge with this class of drugs [60].
•  mABs: Monoclonal antibodies directly inhibit EGFR outside the cell by bind­
ing to the extracellular domain and preventing ligand binding. Antibodies 
have some important advantages over small molecules: being proteins their 
metabolitic pathways are well understood and completely safe and they exibit 
high affinity and selectivity. On the other hand, however, they also exibit the 
typical drawbacks of biotechnological drugs: they are expensive and difficult to 
manifacture and store, have a short shelf-life due to denaturation and degrada­
tion, they axe not suitable for oral administration, they’re often immunogenic 
and susceptible to enzymatic degradation in vivo.
5.2 Aims
Focus of this part is to employ the haptic-based approach alongside traditional molec­
ular modelling techniques to the design and optimisation of anti-EGFR drugs, on the 
one hand to test its performance on a real drug design project and on the other to
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achieve the design of structures of interest. Both lead optimisation of existing struc­
tures (from drugs currently in the market, in clinical trials or inhibitors described 
in the literature) and de novo design approaches have been used. The target is the 
inhibition of the kinase activity of EGFR and other members of his family, both 
in a traditional way with molecules that compete with ATP for the active site and 
targeting a protein-protein interaction essential for the activation of the enzyme.
5.3 Validation of docking algorithm
At the time when this project was started the Protein Data Bank [61] hosted 7 
different structures of the EGFR kinase domain, shown in Table 5.3.
PD B  Code description resolution (A)
1M17 human EGFR with Erlotinib 2.6
1M14 human EGFR (apoenzyme) 2.6
2J5E human EGFR with 13-JAB 3.1
2J5F human EGFR i with 34-JAB 3.0
2GS6 human EGFR with an ATP-analog-peptide conjugate 2.8
2GS7 human EGFR (apoenzyme) 2.8
1XKK human EGFR with Lapatinib 2.4
Table 5.1: EGFR kinase domain crystals in the Protein Data Bank
Several small molecules have been co-crystallised with the EGFR kinase domain. 
Quinazoline derivatives, in particular, are well represented. This class of compounds 
have been chosen to validate the docking protocol. The analysis of the crystals showed 
that quinazoline is involved in a water bridge with the active site (probabily with the 
side chain of Thr766). That water molecule was therefore kept in every docking simu­
lation. The docking algorithm was able to retrieve the crystallographic pose for all of
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the tested molecules (with the exception of lapatinib) in their own crystal structure 
and in cross-docking experiments on 1M17 (co-crystal with erlotinib). The reasons 
why lapatinib’s pose could not be retrieved are discussed in section 5.5. Quinazoline 
was docked as well to validate a fragment-based approach and his crystallographic 
pose was successfully retrieved. Figure 5.8 shows some of the results.
Figure 5.8: Quinazoline (yellow) and Erlotinib (green) docked poses compared to 
Erlotinib crystallographic pose (black)
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5.4 Investigating EGFR plasticity
The understanding of the conformational balance of a protein is essential in the design 
of inhibitors. Crystal structures of the EGFR kinase domain have been determined in 
the literature in two distinct crystal lattices. In one the kinase domain is unphospho- 
rylated but adopts an active conformation, either in a ligand-free form or in complex 
with the cancer drug Erlotinib (Tarceva) [53]. The EGFR kinase domain in a second 
crystal form [62] is bound to the drug Lapatinib (Tykerb), or obtained through a mu­
tation [54] and is in an inactive conformation that resembles closely that of inactive 
Src-family kinases and cyclin-dependent kinases (CDKs).
To elucidate the structurale rationale for the activation state of the enzyme, 20 
different structures from the Protein Data Bank were superimposed (Figure 5.9) to 
analyse the main differences.
In the inactive conformation the axis of the a -C Helix resulted to be rotated, 
allowing the activation loop to fold back and close the access to the peptide binding 
site.
5.5 Analysis of different inhibition modes
Among quinazoline analogues several compounds show remarkable features that out­
line different inhibition modes. Four candidates were chosen and analysed to provide 
structural insight for their binding mode. Figure 5.10 shows the structures of the four 
molecules.
Three of the compounds (Erlotinib, Gefitinib and Lapatinib) are crystallised in 
their binding mode, while the forth has a very similar analogue crystallised in the 
Protein Data Bank (PDB code 2J5E), and docking experiments confirmed that it is 
very likely to mantain the same binding mode. In all four compounds the quinazoline 
moiety appears to bind to the hinge region in the same way, with the interactions 
outlined in the previous section.
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II
Figure 5.9: Superimposition of 20 crystallographic structures: the active ones are 
shown in red, the inactive in blue. The shift of the activation loop and the rotation 
of the a-C helix are clearly visible
67
Gefitinib
Erlotinib
Lapatinib
Cl 1033
Figure 5.10: Structures of EGFR inhibitors used in the study
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Some important pharmacokinetic properties for these compounds are shown in 
Table 5.2.
Inhibitor Ki (nM ) Complex Half-life (min)
Erlotinib 0.7 less than 10
Gefitinib 0.4 less than 10
Lapatinib 3.0 300
CI1033 30 (IC50) oo
Table 5.2: Pharmacokinetic properties of some quinazoline-derivated TKIs
Cl1033 is an irreversible inhibitor and in its binding pose the Michael acceptor 
moiety is pointing towards a cysteine residue (Cys797) in the active site. It is capable 
of covalently binding to the sulphur and thus its complex half life is virtually infinite. 
Erlotinib and Gefitinib are both on the market as anticancer drugs (Tarceva and 
Iressa). They show comparable inhibition properties. Lapatinib, on the other hand, 
exhibits a much higher complex half-life.
It has been reported that Lapatinib is selective for the inactive form of EGFR 
kinase domain and can somehow lock the enzyme into the inactive conformation [62]. 
In fact it is the only one inhibitor so far co-crystalised with the enzyme in the inactive 
conformations.
Docking experiments were used to find a rationale for the difference in Lapatinib’s 
binding mode from the ones of the other inhibitors. Each molecule was docked into 
the receptor in both its active (PDB code 1M17) and inactive (PDB code 1XKK) 
conformation (Figure 5.11).
Erlotinib, Gefitinib and CI1033 were successfully docked in the protein in both 
conformational states. Lapatinib docking, unfortunately failed for both the active 
and the inactive crystal. This originates from a limitation of the docking approach, 
as the inactive crystal (1XKK) is actually a co-crystal with Lapatinib itself. The
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IFigure 5.11: Cross docking experiments on the active and the inactive conformation: 
CI1033 (A), Gefitinib (B) and Erlotinib (C) dock in the same position in both crystals. 
Blue poses are obtained on the inactive conformation of the enzyme, red poses refer 
to the active conformation
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molecule’s dimensions and flexibility make it a very difficult example of ligand for 
molecular docking.
A simple superimposition of the crystaflographic pose to both enzyme structures fol­
lowed by energy minimisation was therefore used, and its results revealed a structural 
rationale for Lapatinib’s selectivity: In the inactive conformation a small subpocket is 
present that accomodates the phenyl moiety of the drug. In the active one, however, 
the a-C helix shifts towards the ATP binding region and closes that pocket. Figure 
5.12 shows the enzyme surface and its interactions with the drug. Blue regions are the 
ones that are predicted to negatively interact with the drug. In the active conforma­
tion the steric clash of the phenyl ring with the protein is clearly visible. Developing 
inhibitors able to bind in this region and stabilise the inactive conformation could be 
an interesting way to improve anticancer potency and selectivity.
5.6 Design of a selective TKI drug
Tyrosine Kinase inhibitors are designed to bind in the active site and to compete 
with ATP for its binding pocket. The general pharmacophore of TKIs [63], with some 
exceptions, can be reduced to: an aromatic group with up to three hydrogen bond 
donor-acceptor moieties, to mimic adenine and bind to the hinge region backbone, a 
second aromatic group directed to an hydrophobic poket (sometimes known as the 
kinase selectivity poket) that controls selectivity, a linker between the two aromatic 
groups.
The first group is very often either quinazoline, pyrido-pyridine or pyrido-pyrimidine.
As the adenine-binding pocket is highly conserved among kinases, it was decided to 
keep quinazoline as a binding fragment and focus the design on the kinase selectivity 
pocket, following a fragment based approach was therefore chosen. A library of 206 
fragment-like molecules (obtained from Enamine) was virtually screened. The binding 
site was restricted to the kinase selectivity pocket and the best scoring fragments were 
eye-inspected for their interactions with the enzyme.
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BFigure 5.12: Lapatinib binding: red regions represent favorable binding, blue regions 
represent clashes and repulsions. Lapatinib’s binding poses in the inactive conforma­
tion (A), and in the active one (B) are shown
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6-Hydroxyl-dihydroquinolinone (Figure 5.13) was be a promising group to bind to 
this pocket and was selected for further in silico investigation.
Figure 5.13: Lead Fragment: 6-hydroxy-dihydroquinoline-2(lH)-one
The haptic-based approach was then applied to refine the lead fragment. The 
fragment was used to probe the forces in the selectivity pocket, and per atom scoring 
was used to predict which portion of the fragment were essential for binding. As the 
amide group was not predicted to be crucial for the interaction with the molecule it 
was eliminated in successive runs. The absence of the bulky carbonyl group seemed 
to allow for an even better orientation of the hydroxyl for its hydrogen bond (with the 
backbone of AT43). An unsaturation was also introduced to avoid prochirai centers 
and boost hydrophobicity. Hydroxynaphtalene was therefore chosen as a fragment 
and its pose was confirmed by docking experiments.
The following step was establishing a good linker bridge between the two aromatic 
portions, that was able to allow both fragments to bind with the correct orientation. 
A set of analogues, differing just for the linker bridge, were built and docked into the 
active site. Ethylene (Figure 5.14) seemed to provide the right distance and angle 
to allow the two aromatic portions to mantain the binding modes each showed when 
docked alone.
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OH
Figure 5.14: Lead design: ethylene bridge
Figure 5.15: Lead design: proposed lead. The fragment binding in the selectivity 
poket forms an hydrogen bond w ith the backbone of A743
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5.7 Design o f a EGFR allosteric inhibitor
As data about Lapatinib binding mode have pointed out, control over the active/inactive 
conformational balance of EGFR and possibly other members of the HER family could 
be the key to a selective and potent inhibition of this family of receptors. It has been 
demonstrated that EGFR kinase domain is capable of auto-regulating its activation 
state in trans [53]. The present model for EGFR activation considers the kinase 
domain to be autoinhibited and constrained most of the time in the inactive con­
formation. Upon ligand activation the extracellular domains of two HER members 
dimerise, so that their kinase domains are brought at a close distance. This allows 
the formation of a kinase domain dimer. The C-lobe of one domain trans activates the 
other by binding to the a-C helix region of the other and stabilising the active con­
formation. Mutations of some key amino acids in the interaction interface has been 
proved to prevent the kinase activity and lock EGFR in an inactive form [53]. This 
interaction is peculiar to this family of receptor. Being able to target this interface[64] 
and disrupt the interaction between the two kinase residues with a small drug-like 
molecule would therefore be the first step towards a new class of selective and potent 
anti-EGFR drugs.
5.7.1 Choice of the target
An analysis of the general characteristics of the two interface surfaces was carried out 
in order to choose which one was the most attractive for the inhibitor binding (Figure 
5.16). The C lobe one was chosen as the most promising one. The main reasons for 
this choices are illustrated below:
• Its structure is conserved in each EGFR crystal structure, and its shape is well 
defined, while the N lobe one appears to be highly flexible.
• The molecular surfaces presents some clefts and pseudopockets that could fit a 
small molecule.
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Figure 5.16: Interaction Surfaces: C lobe (top) was preferred over N lobe (bottom )
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• The sequence of this region is more conserved among the HER family members. 
An inhibitor taxgetting this surface is therefore more likely to be cross-active.
•  It has the same conformation in both the active and the inactive form of the 
kinase domain, which should in theory allow the molecule’s binding to be inde­
pendent form the activation balance of the receptor.
•  The binding of a small molecule to this region is highly unlikely to affect the 
active/inactive balance of the kinase itself, while it is reasonable to think that 
a molecule targeting the N lobe surface might disrupt the protein-protein inter­
action while still keeping the kinase in its active conformation.
5.7.2 Virtual screening approach
1XKK was selected as target structure. In the PDB file Met945 side chain is not 
present, and was added using 2GS7 (V924R mutant) as a template. A large database 
from Enamine comprising 18143 structures was virtual-screened, docking each molecule 
on the C lobe interaction surface of the crystal. Among the top scoring molecules the 
one in Figure 5.17 appears particularly promising. Figure 5.18 shows the predicted 
binding pose of the molecule.
Figure 5.17: Structure of lead
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Figure 5.18: Predicted binding mode
Even though it is not binding directly to the interacting residues of the interface, 
superimposition of this binding mode to the EGFR kinase dimer (Figure 5.19) shows 
that this molecule could clash with the second monomer thus interfering with the 
complex.
5.7.3 In vitro tests
The compound was synthesised and in vitro test were carried out for the compound 
on four different cancer cell lines. Results are shown in Figure 5.20.
From these preliminary results the molecule appears to be active on some of the 
cell lines in the low micromolar range. This is result is very important considering that 
the inhibition of the dimerisation of the kinase domains of EGFR is not a validated 
target.
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Figure 5.19: Inhibitor in the dimer structure
Figure 5.20: In vitro activity data
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5.7.4 Considerations on other members of the family
EGFR activation pathway is partially redundant. Selective inhibitors in vivo have to 
face the compensation by other HER receptors of the impaired EGFR kinase activity. 
There is growing interest in the development of molecules capable of inhibiting dif­
ferent related kinases. Lapatinib is one of these dual inhibitors, being able to inhibit 
both HER1 and HER2[65]. Since different members of the HER family are thought 
to be able to form heterodimers with one another, it is reasonable to suppose that 
the interacting surfaces are fairly conserved in at least some of the kinases. These 
interfaces were studied to predict if the selected molecule could be able to bind to 
other EGFR family members and act as a selective multi kinase inhibitor.
The structure of HER2, HER3 and HER4 have not been solved yet. Homology 
models based on the EGFR structure have therefore been built from the sequences 
of the three kinases and compared to 1XKK. The sequences have been aligned using 
MOE 2007.09. Ten models for each were predicted using the same sofware and the 
best scoring one was chosen in each case and inspected for deviations in terms of 
inter-residue diheadral angles and bond lengths. No adjustments to the structures 
were needed.
In particular the amino acids surrounding the predicted binding pose (less 4.5 
A away from any of the ligand’s atoms) were investigated. Table 5.3 shows the 
differences in the sequences in the area of interest:
HER3 appears to be less related to EGFR than the other two. This protein, 
unlike the rest of the family is catalytically inactive. However it is thought to be 
able to activate the others in trans by forming an asymmetric dimer with their kinase 
domain. The C lobe interface is in fact well conserved in all the generated homology 
models. The putative binding site for the lead molecule (Figures 5.21, 5.22 and 5.23 )
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residue identity with EGFR
HER2
78.9 %
HER3
59.2 %
HER4
78.5 %
D942 D D D
V943 V V V
M945 M M M
1946 I V V
K949 K K K
P959 P P P
K960 R T K
E963 E E E
L964 L L L
1966 S N A
E967 E E E
F968 F F F
K970 R R R
M971 M M M
Y978 F Y Y
Table 5.3: Comparison of the binding site residues: conserved residues are shown in 
black, conservative mutations in blue and non conservative mutations in red
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is very similar and all the non conservative mutations axe far enough from the ligand 
to predict it as a possible multi HER kinase inhibitor.
Modelling results are very incouraging as they predict a possible cross-activity of 
a molecule tar get ted to the interface on all the members of the HER family.
Figure 5.21: Her2 homology model: HER2 is shown in green and EGFR in yellow for 
comparison
5.7.5 Lead optim isation
The predected pose for the putative interface inhibitor was used as a starting point 
for a lead optimisation project aimed at the design of more diverse structures which 
would retain and possibly increase the inhibitory potential.
This project was carried out by a project student using the haptic-based approach 
described earlier. An analysis of the binding pose revealed that three out of the four 
benzene rings fit in hydrophobic pockets on the surface of the enzyme, while the forth 
seems to have limited interactions with the protein. Starting from an analysis of
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Figure 5.22: Her3 homology model: HER3 is shown in green and EGFR in yellow for 
comparison
Figure 5.23: Her4 homology model: HER4 is shown in green and EGFR in yellow for 
comparison
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these three pockets and of the aminoacids surrounding them, a library of fragments 
was derived, and each one was tested with the haptic device for interaction with 
the protein. The more favourable fragments were grown into bigger portions and 
retested. The process was repeated several times till the single fragments merged into 
molecules, which were finally docked to confirm their poses. Four among the resulting 
compounds, whose poses are all confirmed by docking, appeared to be particularly 
significant and are shown in Figures 5.24, 5.25, 5.26, 5.27.
5.7.6 Peptidomimetics approach
Drug design often takes natural ligands as templates, and surface inhibitor design 
is no exception [66]. As an alternative route to design an inhibitor to target EGFR 
kinase domain dimerisation interface the interacting residues of the two monomers 
were considered. Residues 916-926 form a small a  helix, that in the dimer interacts 
tightly with the surface on the N lobe.
The synthesis and in vitro testing of the activity of this portion could provide 
insight on viability of the dimerisation interface as a target.
Molecular dynamics simulations were performed to predict the stability of the helix 
in solution. A peptide with sequence: CTIDVYMIMVKCW, corrisponding to AAs 
915-927 was allowed to evolve for 20 ns from an a  helix structure. As shown in Figure 
5.28, the Tryptophan residue at the C term resulted to be very flexible and its side 
chain movements were thought to compromise the stability of the secondary structure. 
A second dynamics was run mutating the tryptophan to alanine, which improved the 
stability of the helix in the simulation. The deleted form (CTIDVYMIMVKC) was 
also investigated, and appeared to be more stable than the other two, and was there­
fore chosen for the second step. A complex between the helix and the kinase monomer 
was generated, and allowed to evolve for 5 ns in a molecular dynamics simulation. 
As shown in figure 5.29 the complex remained stable and all the main interactions 
between the protein and the peptide were conserved for the whole duration of the 
simulation.
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H(a) Compound SI: structure
(b) Compound SI: docked pose 
Figure 5.24: Fragment based lead optimisation: compound Si
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(a) Compound S2: structure
(b) Compound S2: docked pose 
Figure 5.25: Fragment based lead optimisation: compound S2
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(a) Compound S3: structure
(b) Compound S3: docked pose 
Figure 5.26: Fragment based lead optimisation: compound S3
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(a) Compound S4: structure
(b) Compound S4: docked pose 
Figure 5.27: Fragment based lead optimisation: compound S4
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Figure 5.28: Helix stability studies: structure of the helix at the beginning and after 
4 ns
5.8 C onclusions
The haptic based approach was applied to the development of inhibitors of the EGFR 
pathway together with other more traditional drug design approaches. Both in the 
case of active site inhibitors and allosteric inhibitors the approach was considerabily 
useful in the process of lead identification and optimisation allowing a direct interven­
tion of the user and a rapid test of hypotheses. The application resulted in a molecule 
that shows biological activity in in vitro tests.
89
Figure 5.29: Complex stability studies: structure of the complex at the beginning 
and after 5 ns
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Chapter 6
Lead O ptim isation o f an A nti-H C V  
Polym erase Inhibitor
6.1 H epatitis C virus
Since its discovery in 1989, hepatitis C virus (HCV) has been recognised as a major 
cause of chronic liver disease and affects approximately 200 million people worldwide 
at the present time[67, 68], representing nearly 3% of the world’s population. Per­
sistent infection with. HCV is associated with the development of chronic hepatitis, 
hepatic steatosis, cirrhosis, and hepatocellular carcinoma. In general, chronic hepati­
tis C infection is relatively asymptomatic and have few, if any, clinical manifestations 
prior to the development of cirrhosis.
The approved therapy for HCV infection shows only limited efficacy and no effec­
tive vaccine has been developed. [69, 70]
Liver disease associated with HCV infection is the leading indicator for liver trans­
plantation in the United States.
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6.1.1 Genom e organisation
HCV is a small, enveloped RNA virus belonging to the Hepacivirus genus of the 
Flaviviridae family, which also includes several classical flaviviruses, including Dengue 
virus and Yellow Fever virus, as well as pestiviruses, such as Bovine Viral Diarrhea 
virus and the unassigned GB viruses [9,10]. The HCV genome consists of an RNA 
molecule, of approximately 9.6 kb, that contains a large open reading frame flanked 
by structured 5’ and 3’ non-translated regions (NTRs).
Viral proteins are translated as a polyprotein precursor via an internal ribosome 
entry site (IRES) located in the 5’ NTR. The polyprotein undergoes a complex series 
of co- and post-translational cleavage events catalyzed by both host and viral pro­
teases to yield the individual HCV proteins. The 10 HCV proteins are organized in 
the polyprotein in the order: NH2-C-El-E2-p7-NS2-NS3-NS4A-NS4B-NS5A-NS5B- 
COOH[69]. An additional HCV protein, F (for frameshift protein) or ARFP (for 
alternate reading frame protein), generated by an overlapping reading frame in the 
core (C) protein coding sequence, has been proposed[71].
fcVtnon
g. Virion
Figure 6.1: HCV life cycle. [72]
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6.2 N S5B
NS5B is a 68-kDa protein with a conserved sequence motif characteristic of viral 
RNA-dependent RNA polymerase (RdRp), including a hallmark GDD motif that 
produces catalytic activity [69]. NS5B is a tail-anchored protein and its C-terminal 
21-aa region forms an alpha-helical transmembrane domain, which is dispensable 
for polymerase activity in vitro but is responsible for post-translational targeting to 
the cytoplasmic side of the ER [67]. Analysis of the crystal structure of NS5B has 
revealed that the HCV RdRp resembles a right hand and contains fingers, palm, 
and thumb subdomains, similar to other template-dependent polymerases. Unlike 
the more open structures of other template-dependent DNA polymerases, such as the 
Klenow Fragment and the human immunodeficiency virus 1 reverse transcriptase, the 
HCV RdRp has a fully encircled active site through extensive interactions between 
the fingers and thumb subdomains, resulting in a protein that predominantly exists 
in a “closed” conformation.
The success of antiviral therapies based on chemotherapeutic agents targeting viral 
polymerases has prompted intense efforts to develop inhibitors of HCV NS5B. Stud­
ies with HIV reverse transcriptase validate the clinical utility of two distinct classes 
of viral polymerase inhibitors, nucleoside and non-nucleoside inhibitors. Nucleoside 
inhibitors function as competitive substrate analogs that prevent RNA chain elonga­
tion when incorporated by the viral enzyme, resulting in premature chain termination. 
HIV reverse transcriptase non-nucleoside inhibitors bind to a site residing outside the 
enzyme active site and inhibit catalysis by an allosteric mechanism. Several putative 
allosteric binding sites on the surface of HCV NS5B have been suggested based on re­
cent structural studies, and several chemical classes of NS5B non-nucleoside inhibitors 
have been described. [73].
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6.3 The ProTide approach
The first example of aryloxy phosphoramidate was reported in 1992 [74] as prodrugs 
of AZT. Further development of the approach resulted in ProTides containing alkyl or 
haloalkyl esters in place of the aryl moiety and structure activity relationship studies 
of the amino acid side chain [75, 76].
The two masking groups represented by the aminoacid ester and thee aryl moi­
ety increase the lipophilicity of the molecule allowing the nucleotide monophosphate 
on passive diffusion into the cell. The activation results in the release of the free 
monophosphate, bypassing the first step of phosphorylation[77].
The phosophoramidate approach was later successfully applied to a number of 
different nucleotide analogues greatly improving their antiviral or anticancer activity.
6.4 Aims
2’-Methyl guanosine (Figure 6.2 is a known inhibitor of NS5B polymerase activity [78]. 
The protide approach has been successfully applied to this drug to bypass the first 
phosphorylation step dramatically increasing the availability of the monophosphate 
form inside the cell. This project is focused on the optimisation of the parent drug 
and the exploration of its structure-activity relationships, and aims to the discovery 
of derivatives with a better selectivity and activity profile and enhanced pharmaco­
dynamic properties [79, 80].
6.5 M odel building and refining
HCV NS5B is one of the most challenging enzymes for docking programs [81]. Al­
though crystallised many times under different conditions, there is no reliable struc­
ture of the complex with a template RNA strand to date, which is essential for 
structure-based approaches to the design of nucleoside analogue inhibitors. Its high
94
HO
HO
O
//
•Px  
/  O
o
w
-p
HO
O
N NH
N
OH OH
Figure 6.2: Structure of the lead compound
degree of flexibility (common to all the polymerases) and the presence of not com­
pletely understood allosteric regulation mechanisms make the task of building a model 
even more challenging. On the positive hand, however, the literature on the field is 
copious and provides a relevant amount of experimental data that can be used for 
validation purposes. In particular, Merck has published a paper [73] describing the 
consthiction and validation of a model for NS5B nucleoside analogue inhibitors. An 
approach similar to what they describe has been followed initially to build a model.
A crystal structure of NS5B (PDB code 1GX6) and one of the bacteriophage 
0 6 RNA-dependent RNA polymerase (PDB code 1H10) were superposed. 1H10 
is crystalised in the initiation complex with an incoming NTP, a primer, various 
metal ions and a template strand. These were copied into the NS5B active site and 
then energy minimised to correct the geometries (using the MOE implementation 
of MMFF94x). Preliminary docking studies on the model confirmed its ability to 
dock active GTP inhibitors in the pocket. However 2’C-Me-GTP, the lead structure, 
although correctly form ing the base paring interactions, appeared to be too far from
95
S B sss
the protein to justify the evidence for its inactivity on the S282T mutant. The region 
close to the 2’C appeared to be very open, while it is believed that region is closely 
interacting with the ligand, selecting ribonuclotides over deoxy-ribonuclotides. A 
structural refinement stage was therefore necessary before the model could be used. 
This was done by running a short molecular dynamics simulation on the protein- 
ligand complex. GROMACS was used to run the simulation for 4 ns of simulated 
time. The trajectory was analysed, monitoring the distance between the C’ Methyl 
and Ser282 as a parameter. The result showed that the distance was shortening, 
while the overall structure of the enzyme and the base pairings remained constant. 
The snapshot with the m inim um distance was chosen, and further minimised with 
MMFF94x.
Docking tests confirmed the minimised model to be in general more predictive 
than the non minimised one.
6.5.1 Model for uracil binding substrates
The template strand in the model is a poly-dC oligonucleotide. While this is appro­
priate to model the binding of 2’C-Me-GTP and most of its derivative, some modifica­
tions on the purine base required the investigation of possible paring with a different 
base. Therefore a model with a uracil-based template was also built. This was done 
by mutating the last cytidine base (the one paring with the inhibitor) to uracil, min­
imising the structure (in its apo form) and then minimising again with 6-Me ATP 
in the binding site, to get optimal orientation for the base paring. The building of 
the other two possible models (with purines as template) was not necessary, since the 
investigation of possible base mutants was not extended to pyrimidines.
6.5.2 Model validation
The docking approach was validated in its ability to retrieve the pose of the lead 
molecule. Docking results of the triphosphates were rather poor. This is probabily
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because the triphosphate chain is charged and highly flexible, therefore able to adapt 
itself to the pocket and to form very strong interactions that can prevail on the base 
paring and lead to mis-score bad poses. The docking of nuclosides, besides being much 
faster (around 6-fold), yielded much better results. The sugar, however, appeared to 
be very flexible and its position was very variable from one run to the other. The 
docking of nucleotides (monophosphated nucleosides) improved the results, locking 
the 5’ C in its correct position and therefore constraining the orientation of the whole 
sugar.
6.6 SA R
Figure 6.3 shows the main positions that has been explored for derivatives. Due to 
the high degree of approximation of the model and the non-trivial correlation between 
binding and activity, the binding affinity of the modelled compounds had to be studied 
in a semi-quantitative if not qualitative fashon. Poses were analysed focusing on the 
mantainment of a correct base pair alignment and a good position of the sugar in the 
active site. The number and the orientation of hydrogen bonds with the protein and 
the presence of other weak interactions was also considered.
1
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Figure 6.3: Structure activity relationship.
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6.6.1 2’ substitutions
NS5B is naturally able to select nucleotides over deoxy-nucleotides. It is thought that 
this is due the 2’OH donating an hydrogen bond to Asp225 side chain[82]. However 
-F derivatives have been reported to have strong activity[82], suggesting a possible 
role for hydrogen bond acceptors as well in this position. Docking studies confirm the 
binding of 2’-F derivatives.
The structures of the modelled compounds are reported in Figure 6.4 and the 
predicted affinity summarised in Table 6.1.
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Figure 6.4: 2’ modifications
Compound Score
A-1 V
A-2 X
A-3 V
Table 6.1: predicted affinity: X weak binding or not binding in the conventional pose,
V binding in the conventional pose, W  strong binding in the conventional pose
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As expected the fluoro derivative (compound A-1) shows a promising interaction 
profile (Figure 6.5). The methyl group in the 2’ position of the parent drug causes 
steric interference and doesn’t allow the next nucleotide to bind correctly after the 
drug is incorporated. However extending this substituent causes a worse binding of 
the drug to the protein. 2’Ethyl derivatives (compound A-2, docking pose in Figure 
6.6) are predicted to be less active (as confirmed by in vitro studies) and the propyl 
derivative (compound A-3) completely prevents binding (and is inactive in vitro).
Figure 6.5: Docking results of the 2’F derivative: the binding pose of the parent 
molecule is conserved, and the fluorine atom in 2’ accepts an hydrogen bond
6.6 .2  3 ’ su b stitu tion s
The structures of the modelled compounds are reported in Figure 6.7 and the pre­
dicted affinity summarised in Table 6.2.
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VFigure 6.6: Docking results of the 2’ethyl derivative: the binding pose is similar to 
that of the parent molecule, but steric interactions of the ethyl group cause a shift in 
the position of the sugar
Compound Score
B-l V
B-2 W
B-3 w
B-4 w
B-5 V
B-6 V
B-7 V
B-8 V
B-9 V
B-10 V
Table 6.2: predicted affinity: X weak binding or not binding in the conventional pose,
V binding in the conventional pose, W  strong binding in the conventional pose
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Figure 6.7: 3’ modifications
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The 3’ OH is involved in an hydrogen bond with the enzyme. 3-Deoxy nucleotides 
axe a common strategy in polymerase inhibition, because they act as chain terminators 
since they do not provide a free OH for the condensation of the incoming nucleotide. 
The docking of the 3’-deoxy derivative (compound B-l) showed that the drug still 
fits in the active site, but the orientation of the sugar appears to be much more 
variable (Figure 6.8). The loss of the hydrogen bond seems to cause instability in the 
sugar and the binding is therefore probabily less effective. This unfortunately can 
not be confirmed with activity in vitro tests, as the 3’deoxy nucleotide is acting with 
a different mechanism (chain termination) and is therefore not directly comparable 
in terms of activity data. The keto derivative (compound B-3) shows a particularly 
promising binding pose. The conformation of the sugar is fixed and binding geometries 
appear to be optimal. This molecule is involved in keto-enol tautomerism that extends 
to the 2’ OH. Substituting the 2’ OH (with fluorine for instance, compound B-4) might 
be a good strategy to improve the binding affinity of this class of derivatives.
Many other substitutions appear to be tolerated here, including -F (compound 
B-2, Figure 6.9), di-F (compound B-5, Figure 6.10), 3’-azido (compound B-6), 3’-CN 
(compound B-7), 3’methoxy (compound B-10).
6.6.3 4’ substitutions
The structures of the modelled compounds are reported in Figure 6.11 and the pre­
dicted affinity summarised in Table 6.3.
Compound Score
C-l W
Table 6.3: predicted affinity: X weak binding or not binding in the conventional pose,
V binding in the conventional pose, W  strong binding in the conventional pose
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Figure 6.8: Docking results of the 3 ’deoxy derivative: the binding pose is similar to 
that of the parent molecule, but the position of the sugar is much less defined
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Figure 6.9: Docking results of the 3’fluoro derivative: the binding pose of the parent 
molecule is conserved
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Figure 6.10: Docking results of the 3’gem fluoro derivative: the binding pose of the 
parent molecule is conserved
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Figure 6.11: 4 ’ modifications
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Merck has published a series of 4 ’ Azido derivatives that has showed activity 
against HCV NS5B[82]. To test the predictability of the model, the 4’ Azido derivative 
(compound C -l) of 2’Me guanosine monophosphate was docked (Figure 6.12). The 
position of the base and the sugar are those expected for the parent nucleotide, and 
the azido moiety is accomodated inside a pocket of the active site.
Figure 6.12: Docking results of the 4 ’azido derivative: the binding pose of the parent 
molecule is conserved, the azido group is accomodated in a subpocket of the active 
site
6 .6 .4  2 su b stitu tion s
The structures of the modelled compounds are reported in Figure 6.13 and 6.14 and 
the predicted affinity summarised in Table 6.4.
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Compound Score
D-l V
D-2 V
D-3 W
D-4 W
D-5 V
D-6 V
D-7 w
D-8 V
D-9 w
D-10 V
D -ll V
D-12 V
D-13 V
D-14 w
D-15 w
Table 6.4: predicted affinity: X weak binding or not binding in the conventional pose, 
V binding in the conventional pose, W  strong binding in the conventional pose
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The nitrogen in the 2 position is involved in an hydrogen bond which is essential for 
the base pairing. Substitutions which don‘t, affect the hydrogen bonding capabilites 
of the nitrogen are tolerated, even with bulky substituents. A good example is the 
2N benzyl derivative (compound D-2, Figure 6.15).
Figure 6.15: Docking results of the 2 benzyl derivative: the binding pose of the parent 
molecule is conserved
6.6 .5  6 su b stitu tio n s
The structures of the modelled compounds are reported in Figure 6.16 and the pre­
dicted affinity summarised in Table 6.5.
The 6 keto moiety is involved in the base paring as an hydrogen bond acceptor. 
Its replacement with a primary amine gives an active compound. Although it cannot
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Compound Score
E-l W
E-2 W
E-3 w
E-4 w
E-5 w
E-6 w
E-7 V
E-8 V
Table 6.5: predicted affinity: X weak binding or not binding in the conventional pose, 
V binding in the conventional pose, W  strong binding in the conventional pose
be docked using the conventional model, this compound is successfully docked in the 
model bearing Uracil in the template strand. In fact the compound shows the same 
interactions pattern as adenine (plus an additional hydrogen bond from the amino 
group in 2). However, docking studies also predict a second pose (Figure 6.17), with 
similar binding energy. In this second pose the three hydrogen bonds with uracil are 
conserved, but the coordinates of the nitrogens in 2 and 6 are inverted. Whether this 
second pose is biologically meaningful or is just a docking artifact is not clear, but 
could be investigated by comparing the biological activities of different 2-N and 6-N 
substituted derivatives.
6.6.6 7-8 substitutions
The structures of the modelled compounds are reported in Figure 6.21 and the pre­
dicted affinity summarised in Table 6.6..
7-deaza compounds (Figure 6.22) have been reported in the literature as NS5B 
inhibitors. They usually show a better activity compared to their nitrogen counter-
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Figure 6.17: 6-amino derivative poses. 6 amino compounds show two different binding 
modes.
Compound Score
F-l W
F-2 W
F-3 V
F-4 V
F-5 W
F-6 W
F-7 X
F-8 X
Table 6.6: predicted affinity: X weak binding or not binding in the conventional pose, 
V binding in the conventional pose, W  strong binding in the conventional pose
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Figure 6.18: Docking results of the 6 amino derivative: direct pose
Figure 6.19: Docking results of the 6 amino derivative: inverted pose
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Figure 6.20: Docking results of the 6 benzyl derivative: the binding pose of the parent 
molecule is conserved
" I
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Figure 6.21: 7-8 modifications
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parts. The analysis of the electrostatic potential in the region of binding provided a 
rationale for it. The nitrogen in 7 is pointing towards a negatively charged region. 
The CH in the deaza derivative is polarised, with a partial positive charge on the 
hydrogen. Therefore CH is favoured for electronic (as well as steric) reasons over N 
in the 7 position. To exploit this feature, some 7C substituted compounds has been 
designed and docked. In particular, 7-CBr has shown promising results. The steric 
interaction of bromine appears to be optimal, and a electron withdrawing group in 8 
should be able to induce a positive charge on the bromine atom. The most promising 
compound of this series appeared to be 7-Br, 8-F (compound F-5).
Figure 6.22: Docking results of the 7 deaza derivative: the binding pose of the parent 
molecule is conserved
6.7  C on clu sion s
The project on HCV polymerase resulted in the construction of a model which showed 
good agreement with biological data. It has been used to direct the synthesis of
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D o m a i n  1
D o m a i n  2
D o m a i n  3
Figure 7.1: Structure of the NS3 enzyme
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potentially important as therapeutic agents [91, 98, 99, 100, 101]. The necessity of the 
unwinding activity mediated by the NTPase/helicase enzymes in the viral life cycle 
also has recently been reported in knock-out experiments that demonstrated unam­
biguously that the switch-off of the helicase activity abolishes the virus propagation of 
bovine diarrhea virus (BVDV) and of dengue fever virus (DENV)[102,103]. Inhibition 
of the helicase enzyme has the potential not only to terminate the proliferation of the 
virus but also to indirectly stimulate a cellular antiviral ds RNA sensing machinery 
because of the expected build up of intracellular dsRNA intermediates[104, 105, 106]. 
Recently, a preclinical proof of concept for helicase inhibitors as antiviral agents has 
been obtained for Herpes simplex virus HSV[98, 99, 100, 101]. Using high-throughput 
screening (HTS) and optimization of the screening hits resulted in compounds that 
inhibited HSV growth in cell culture with little cytotoxicity and which were orally ac­
tive in an animal model of HSV[107, 108]. Over the past decade, significant progress 
has been made in the development of selective helicase inhibitors as antiviral and 
anti-cancer drugs[109].
7.1.2 Aims
The standard treatment for chronic HCV infection so far is pegylated IFN- plus 
ribavirin[110]. Although the mechanism of action of these drugs is debated, with 
both antiviral and immunostimulatory mechanisms being implicated, the sustained 
response rates are far from ideal. Moreover, there is substantial associated toxicity 
and the likelihood of success depends on viral and host factors that are often beyond 
the control of patients and physicians, in addition to the high cost [111, 112]. Clearly, 
more effective and less toxic treatment regimens are needed. Among hepatitis C viral 
proteins, NS3 helicase is a valuable but yet largely unexplored target. NS3 helicase 
inhibition is a promising strategy because it has the potential not only to terminate the 
proliferation of the virus but also to indirectly stimulate a cellular antiviral response 
against double-stranded RNA [104, 105, 106, 113]. Moreover despite the presence 
on the market and in clinical trials of several anti-NS5B inhibitors [114], there are 
no marketed NS3 inhibitors. The development of such molecules would be greatly
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beneficial from a combined treatment perspective[115], The NS3 helicase enzyme has 
multiple functional domains that present multiple potential mechanisms of action for 
the design of an inhibitor.
7.2 P revious work
A modelling project previously carried out in the lab has identified a lead molecule 
for inhibiting the HCV NS3 helicase activity [116]. The chemical structure of the 
molecule is shown in Figure 7.2 and its putative interactions with the RNA binding 
site are shown in Figure 7.3.
\
HN O
NH
Figure 7.2: Structure of the lead compound
The molecule has a michael acceptor group capable of forming a covalent bond 
with Cys431, irreversibly blocking the catalytic function of the enzyme. The downside 
of such a reactive group is the potential of aspecific reactivity, which leads to the high 
toxicity of the compound. The aim of the optimisation is therefore substituting the 
reactive moiety with a less reactive group or a reversible binder while keeping or 
even increasing the activity of the whole molecule by possibly extending it to exploit 
further contacts with the active site.
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Figure 7.3: Interactions of the lead compound
7.3 M eth o d s
The in silico optimisation process was done using the fragment-based, haptic-driven 
approach described earlier. This is an ideal application because the process of lead op­
timisation is highly human-biased and the active side, being open and solvent exposed, 
represents a difficult target for docking and traditional de novo approaches. Every 
compound derived from the fragment based approach was validated with molecular 
docking using PLANTS (see appendices for the exact param eterisation).
7.4 H o t sp o ts  id en tif ica tio n
The human-directed approach chosen for the development necessitates a good knowl­
edge of the active site in terms of potential binding sites. The chemical identity and 
of the residues of the pocket was inspected. Potential maps were generated to iden­
tify areas more likely to be involved in hydrogen bonds, salt bridges and hydrophobic 
interactions. The haptic device was then used to probe the pocket with a negativly 
and successively positively charged atom. All the information gathered with these 
three approaches about the chemical properties and the forces of the different areas 
of the pocket were combined with the information from previous docking experiments
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on the active lead to identify a series of hot spots (i.e. residues that can be used to 
form interactions with the growing molecule) for the fragment-based approach.
Arg393: this residue closes the pocket around the double stranded RNA and forms 
a salt bridge with the phosphate chain. This is also the putative binding parner of 
the carboxylate in the lead molecule.
Cys431: the putative target of the michael acceptor. This residue can be used for 
covalent binding.
Arg481: this second arginine is buried in the pocket and can provide a second 
strong interaction to orient a ligand inside the pocket.
Thr295, Thr433: The two hydroxyl groups are close together and appear in good 
orientation to accomodate a group capable of forming two hydrogen bonds (such as 
-OH or = 0 ).
7.5 Fragm ents
This section summarises the most interesting fragments that were selected for the 
linking phase. All the poses shown have been identified with the haptic driven ap­
proach.
benzoic acid (Figure 7.4): This fragment is also present in the lead molecule. In its 
predicted pose it forms a salt bridge with Arg393. The ring is involved in hydrophobic 
interactions with Ala413, Arg393 and Tyr391.
thiophenol (Figure 7.5): The thiol has a potential for forming a disulfide bond 
with cystein 431. Being less reactive than the michael acceptor it is a valid candidate 
for the reduction of the toxicity of the compounds.
amide (Figure 7.6): the oxygen acts as a hydrogen bond acceptor, while the NH2 
donates another hydrogen bond. The distance between the two groups is ideal to 
contact bouth Thr295 and Thr433.
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Figure 7.4: benzoic acid: binding pose chosen with the haptic approach. The car- 
boxy lie group is engaged in a salt bridge with Arg393.
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Figure 7.5: thiophenol: binding pose chosen with the haptic approach. The thiol 
group is in close proximity to Cys431.
Figure 7.6: amide: binding pose chosen with the haptic approach. The carbonyl and 
the amidic nitrogen are involved in hydrogen bonds with Thr295 and Thr433.
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4-carboxy imidazole (Figure 7.7): The carboxylic group forms an hydrogen bond 
with Arg481. The two nitrogens on the ring form two hydrogen bonds with Thr295 
and Thr433.
Figure 7.7: 4-carboxy imidazole: binding pose chosen with the haptic approach. The 
carboxyilic group interacts with Arg481. The nitrogens on the ring are involved in 
hydrogen bonds with Thr295 and Thr433.
7.6 Lead m olecules
After the generation of poses for each fragments, lead molecules were generated by 
linking various fragments in the active site trying to maintain orientations and inter­
actions with the enzyme. Each resulting molecule was docked with PLANTS and the 
poses were confirmed.
Figures 7.8 to 7.17 show the poses of the various leads inside the active site.
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(a) molecular structure
(b) pose within the active site
Figure 7.8: Compound HI. Structure and interactions with the
(a) molecular structure
(b) pose within the active site 
Figure 7.9: Compound H2. Structure and interactions with the enzyme
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.COCr
(a) molecular structure
(b) pose within the active site 
Figure 7.10: Compound H3. Structure and interactions with the enzyme
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(a) molecular structure
(b) pose within the active site 
Figure 7.11: Compound H4. Structure and interactions with the enzyme
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(a) molecular structure
(b) pose within the active site 
Figure 7.12: Compound H5. Structure and interactions with the enzyme
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(a) molecular structure
(b) pose within the active site 
Figure 7.13: Compound H6. Structure and interactions with the enzyme
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(a) molecular structure
(b) pose within the active site 
Figure 7.14: Compound H7. Structure and interactions with the enzyme
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(a) molecular structure
(b) pose within the active site 
Figure 7.15: Compound H8. Structure and interactions with the enzyme
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(a) molecular structure
(b) pose within the active site 
Figure 7.16: Compound H9. Structure and interactions with the enzyme
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HS-
NH
COO'
(a) molecular structure
(b) pose within the active site 
Figure 7.17: Compound H10. Structure and interactions with the enzyme
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Compound H10 (Figure 7.17) was synthesised and tested in vitro on the HCV helicase 
enzyme. It resulted to be an active inhibitor, with an IC50 of 320 nM and a good 
toxicity profile.
7.7 Conclusions
The application of the haptic approach to the design of HCV NS3 inhibitors demon­
strated its applicability to de novo drug design projects. The fragment-based nature 
of the de novo approach makes it ideal to be treated with the application of haptic 
technology because of the lack of inner flexibility of ligands. This offers the possibility 
of directly controlling all the degrees of freedom of a fragment via the haptic stylus. 
The results were consistently in perfect agreement with docking predictions and one 
of the resulting hits showed activity in in vitro tests.
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Chapter 8
Conclusions
This project has resulted in a fully working realtime drug design environment based 
on haptic technology and trimoda! feedback. It has demonstrated the applicability of 
haptics to drug design and the feasability of a human steered approach to molecular 
modelling. The software has been made publicly availible on the internet and is free 
of charge for commercial and non-commercial use. The implementation of different 
haptic devices has been tested, ranging from the extremely low-end nintendo wii 
remote to more professional devices.
The haptic-based software has then been used alongside more conventional ap­
proaches showing its applicability and verifying in practice the importance of the 
direct human contribution in the process of drug design both in the antiviral and 
anticancer fields.
The limitations of the approach have also emerged: the control of the inner degrees 
of freedom of a molecule remains unsatisfactory in real time, and make working on 
complete molecules unpractical in most cases. Though still useful for the rapid testing 
of hypotheses on complete molecules, the approach is certainly more suitable for 
fragment-based solutions.
In the field of fragment-based de novo drug design the haptic approached has 
been demonstrated to be useful and consistently in accord with molecular docking
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prediction. It was also possible to validate it with some in vitro results on both 
antiviral and anticancer drug design.
The application of the haptic-based approach lead to the design of a molecule 
with anti-HCV activity, acting on the helicase enzyme and several other candidates 
which has not been tested yet.
The in silico characterisation of the binding modes of a large numbers of struc­
turally related compounds was carried out using different approaches and helped 
direct the synthesis of future analogues.
The design of an active molecule putatively acting on an unvalidated anticancer 
drug was also achieved, targetting the EGFR kinase dimerisation protein-protein 
interaction. The application of the haptic based approach was essential for the de­
veloping of this lead molecule into a family of structurally different compound.
Future developments of the approach include the introduction of protein flexibility. 
This will significantly increase the computational load of the simulation and will need 
a re-structuring of the code in order to make it run in parallel on multiple CPUs. The 
introduction of protein flexibility should render the simulation more realistic and allow 
for study of a wider range of phenomena.
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A ppendix  A
M aterials and M ethods
A .l  M olecular docking and virtual screening
All docking experiments and virtual screenings were carried out using PLANTS (Pro­
tein Ligand ANT System) v 1.07 [117]. Plants performance for docking and virtual 
screening on a model kinase has previously been investigated at the University of 
Padova [118] and it outperformed most commercial softwares, with an enrichment 
ratio around 7.0 for the top 10% of the test database.
Plants search algorithm is based on Marco Dorigo’s Ant Colony Optimisation 
algorithm [119]. A set of virtual ants explore the conformational space laying trails 
of pheromone to mark good solutions. The pheromone attracts more ants, which in 
turn lay more pheromone. An evaporation operator is used to weaken abandoned 
trails. Solutions are refined using a non-derivative minimisation algorithm (simplex 
algorithm).
The pseudocode of the search algorithm is shown in Algorithm 2.
The default parameterisation was used, with sigma =  1.0 for virtual screening 
and sigma =  4.0 for single docking (See Appendices) . In both cases a Lennard-Jones 
potential was used for the ligand inner clash energy and chemplp was used as the 
scoring function.
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Algorithm  2 PLANTS search algorithm
InitiahseParameters AndPheromones () 
for i =  1 to iterations do 
for j  =  1 to ants do
Sj «— ConstructSolution()
Sj LocalSearch(sj)
M  <— M  U Sj 
end for
stb <— GetBestSolution() 
stb <— RefinementLocalSearch(st6, 0.2) 
M  <- M  U sib 
UpdatePheromones (slb) 
if diver sificationCriteriaM et then  
Apply SearchDiversification() 
end if  
end for
return best solution found, M
For virtual screening the five different poses generated for each ligand were rescored 
using the MOE scoring function (scoring, svl). This has been shown to increase the 
performance of the virtual screening[118].
A .2 M olecular dynam ics
All Molecular Dynamics simulations were carried out using GROMACS[120] v3.3.1. 
Energy Minimisation was done with a steepest descent algorithm. The exact param­
eters are shown in the appendices (Table B.3).
The solvent relaxation phase was allowed to last for 20 ps using a restrain on 
atomic positions under NPT conditions (constant number of particles, pressure and 
temperature). The exact parameters are shown in the appendices (Table B.4).
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The system was then allowed to evolve without restraints under NPT conditions. 
When not otherwise stated this phase was allowed to last for 5 ns. The exact param­
eters are shown in the appendices ( Table B.5).
A .3 V isualisation and graphics
Molecular Dynamics trajectories were analysed using VMD [121]. All other simu­
lations were analysed in Zodiac and MOE. Ray-traced pictures for this thesis were 
generated using Zodiac, MOE, Pymol [122] and POVRay [123].
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A ppendix  B
Param eters
B .l  M olecular docking and virtual screening
This section includes all the parameters used for PLANTS runs.
aco_ants 20
aco.evap 0.25
acojsigma 5.0
flip_amide_bonds 0
flip .planar _n 1
cluster .structures 5
cluster_rmsd 2.0
Table B.l: Parameters for plants for single docking
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aco_ants 20
aco.evap 0.25
aco_sigma 1.0
flip_amide_bonds 0
flip_planar_n 1
cluster_structures 5
cluster _rmsd 2.0
Table B.2: Parameters for plants for virtual screening
B.2 M olecular dynam ics
This section includes all the parameters used for GROM ACS runs.
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define -DFLEXIBLE
constraints none
integrator steep
dt 0.002
nsteps 2000
nstlist 5
ns_type grid
rlist 0.9
coulombtype PME
rcoulomb 0.9
rvdw 1.4
fourierspacing 0.12
fourier_nx 0
fourier_ny 0
fourier_nz 0
pme.order 4
ewald_rtol le-5
emtol 1000.0
emstep 0.01
Table B.3: Parameters for the energy minimisation .mdp file
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define -DPOSRES
constraints all-bonds
integrator md
dt 0.002
nsteps 10000
nstenergy 10
nstlist 5
ns.type grid
rlist 0.9
coulombtype PME
rcoulomb 0.9
rvdw 1.4
fourierspacing 0.12
fourier_nx 0
fourier_ny 0
fourier_nz 0
pme_order 4
ewa!d_rtol le-5
optimize JFt yes
Tcoupl berendsen
tau_t 0.1 0.1
tc-grps protein sol
ref_t 300 300
Pcoupl berendsen
tau_p 0.5
compressibility 4.5e-5
ref_p 1.0
gen_vel yes
gen_temp 300
gen_seed 173529
Table B.4: Parameters for the solvent relaxation .mdp file
constraints all-bonds
integrator md
dt 0.002
nsteps 2500000
ns.type grid
rlist 0.9
coulombtype PME
rcoulomb 0.9
rvdw 1.4
fourierspacing 0.12
fourier_nx 0
fourier_ny 0
fourier_nz 0
pme_order 4
ewald_rtol le-5
optimize Jft yes
Tcoupl berendsen
tau_t 0.1 0.1
tc-grps protein sol
ref_t 300 300
Pcoupl berendsen
tau-p 0.5
compressibility 4.5e-5
ref_p 1.0
gen_vel yes
gen_temp 300
gen_seed 173529
Table B.5: Parameters for the molecular dynamics .mdp file
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